Tuned polyurethanes for soft tissue regeneration by Jovanovic, Danijela
  
 University of Groningen
Tuned polyurethanes for soft tissue regeneration
Jovanovic, Danijela
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2011
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Jovanovic, D. (2011). Tuned polyurethanes for soft tissue regeneration. Groningen: s.n.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Tuned Polyurethanes for Soft Tissue
Regeneration
Danijela Jovanović





The research described in this dissertation was financially supported by the Research
Institute for Biomedical Science and Application (BMSA; present name: W.J.Kolff
Institute for Biomedical Engineering and Material Science) and the Zernike Institute for
Advanced Materials.
The author gratefully acknowledges the following institutions for financial support in
printing and the distribution of this dissertation: University of Groningen, PolyVation,
InnoCore Technologies and Novozymes.





All rights reserved. No part of this publication may be reproduced or transmitted in any form or by
any means without permission of the author.
RIJKSUNIVERSITEIT GRONINGEN
Tuned Polyurethanes for Soft Tissue Regeneration
Proefschrift
ter verkrijging van het doctoraat in de
Medische Wetenschappen
aan de Rijksuniversiteit Groningen
op gezag van de
Rector Magnificus, dr. F. Zwarts,
in het openbaar te verdedigen op




geboren op 19 september 1977
te Niš, Servië
Promotores: Prof. dr. A.J. Schouten
Prof. dr. M.J.A. van Luyn
Copromotor: dr. M.C. Harmsen
Beoordelingscommissie: Prof. dr. R. Bos
Prof. dr. B. van der Lei
Prof. dr. T. Loontjens
Contents
Chapter 1 Introduction to the thesis 7
Chapter 2 Hydrolytic degradation of polyacylurethanes in vitro 33
Chapter 3 Polyacylurethanes as novel degradable cell carrier materials for
tissue engineering
53
Chapter 4 Novel biomedical polyurethanes based on oligo(-caprolactone-
co-γ-butyrolactone) copolymers via chemo-enzymatic pathways
67
Chapter 5 Novel polyurethanes with interconnected porous structure
induce in vivo tissue remodeling and accompanied
vascularization
91
Chapter 6 General discussion and perspectives 117
Chapter 7 Summary 131




Introduction to the thesis

Introduction to the thesis
9
Soft tissue replacement and functional restoration
Soft tissues connect, support or surround other structures and organs of the body. The
term "soft tissue" applies to the skeletal muscles, fat, and connective tissue along with
the vessels and nerves supplying these components. In general sense, it also applies to
all organs (e.g. heart, brain, liver, kidney). Acute and chronic injury may cause transient
or permanent damage to organs and soft tissues. Nature’s response to damage is to
engage in physiological repair mechanisms (Fig. 1). These, however, may not provide
the adequate restoration of the tissue or organ function or even cause adverse repair
and remodeling, such as fibrosis. Therefore, alternative approaches for restoration and
repair have to be applied, the most dramatic example of which is organ transplantation
(Fig. 1). The damaged (or lost tissues) could be completely replaced by durable
prostheses (graft) of biological or synthetic origin (e.g., heart valve prosthesis, cardiac
pacemakers). With the advances in medical and natural sciences, new approaches
focused on exploiting body’s own ability to regenerate, facilitated with degradable
instead of durable (non-degradable) materials started gaining interest. Tissue
engineering and regenerative medicine (TERM) approaches are promising to functionally
restore or even regenerate organ or tissue function. TERM is the mimicking of nature’s
own regeneration mechanisms and thus requires the generation of regenerative
microenvironment, which may comprise of any or a combination of cells, instructive
factors and a scaffold.




Biological grafts can be autologous, i.e. from the patient, allogenic, i.e. from a donor or
xenogenic, i.e. harvested from an animal. For instance, to treat damaged vasculature,
three different types of grafts of biological origin could be used1 (Table 1).







































































































nerves < 3 cm);
Polyglycolic acid
*GA – Glutaraldehyde.
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With respect to the immunologically related issues, autograft would be optimal to use.
Unfortunately, in most of the implications, the quality and availability of the patients own
“material” is limited. In those cases, allografts are preferred above xenografts. However,
allografts are related to viral and bacterial infections due to the complications of proper
preparation and processing of human cadaveric tissue6.
Due to the drawbacks given above, an alternative approach led to the development of
synthetic prostheses.
Synthetic prostheses for the replacement of damaged soft tissues are mostly
manufactured from (bio)medical grade polymers and specially designed to fulfill the
function of the tissue they are replacing. Synthetic materials posses the following
advantages relevant to biological grafts: 1) limited batch-to-batch variations, 2)
adjustable/adaptable properties and 3) absence of unknown pathogens.
Since the 1970s, in addition to the already mentioned biological grafts for the treatment
of damaged blood vessels, synthetic vascular prostheses are also available1. These
synthetic grafts are manufactured from poly(ethylene terephthalate) (PET; Dacron®) and
poly(tetrafluoroethylene) (PTFE; Gore-Tex®). Other polymers such as Nylon® and
polyurethanes (Corethane®, Biomer®) have also been utilized with variable success.
It was first believed that artificial grafts should be non-degradable and as bio-inert as
possible. Therefore, most of the artificial graft materials listed in the Table 1 are
biostable. However, clinical practice showed that Dacron® and Gore-Tex® can only be
applied in the repair of large diameter blood vessels (>6mm) since they were occluded
when implanted in the small diameter vasculature sites7, 8. The reason is a compliance
mismatch between the artificial graft and the native artery which results in the
development of intimal hyperplasia at the anastomosis and graft occlusion. Furthermore,
for instance in nerve regeneration, the clinical employment of non-degradable materials
is hampered by occasional local tissue fibrosis, triggered by the implanted material and
nerve compression5. These observations led to an interest in the concept of degradable
grafts and arising additional possibilities such as delivery of cells and/or growth and
other instructive cell factors.
Degradable biomedical grafts
Tissue regeneration strategies have been applied to virtually all soft tissues: nerve
conduits5, cardio-vascular7, 9, skin10, muscle3 etc11, 12. All these treatment modalities
require temporary supports i.e. biomaterials that are tuned to a specific application in
terms of biodegradability, structural support, porosity, strength, stiffness, appropriate
surface properties, biomechanical compliance among others. Scaffolds need to facilitate
loading with cells and growth factors and exchange of oxygen, nutrients and waste13.
Regardless of the mode the scaffold is applied, bare or pre-cultured with relevant cells,
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in order to provide viable cell environment, the porous structure must allow
vascularization14. The latter is only possible if the scaffold is highly porous with
interconnected channels.
Porous scaffolds for soft tissue replacement can be manufactured using a variety of
methods (Table 2)15, 16. All the methods can be divided into: non-design controlled and
design controlled scaffolds. Design-controlled manufacturing method, i.e. rapid
prototyping (also known as solid free-form technique) are computer aided-fabrication
processes and are therefore, of newer date. Non-design controlled manufacturing
methods cover a broad range of melt- , gas- and solvent- processing techniques. All
these methods have their pros and cons. Therefore, a choice of the manufacturing
method depends firstly on the material physio-chemical properties, and the consensus
between the advantages and disadvantages of the technique.
Degradable biomedical grafts can be fabricated from naturally occurring polymers,
synthetic polymers or the combination of the two.
When designing porous scaffolds for TERM, the following properties of biological tissues
should be mimicked: 1) architecture, 2) support, 3) strength / elasticity / flexibility, 4)
growth factor delivery / binding and 5) possibility of turnover, i.e. regeneration through
replacement of damaged tissue with novel tissue with the intended, i.e. original,
architecture and function. Depending on the application, mimicking one of the listed
properties might be more important than the other.
Additionally, the scaffold should mimic the properties of the extracellular matrix (ECM) of
the soft tissues that are being regenerated17. Since ECM is mainly composed of proteins
and polysaccharides, most of the scientific research in the field of tissue engineering
focused on: collagen, gelatin, fibrin, hyaluronan, alginate, chitosan and starch. Of these
molecules, alginate, chitosan and starch are derived from non-mammalian and plant
sources, yet exhibit remarkable qualities for tissue engineering. Although these natural
polymers usually warrant appropriate cell adhesion and proliferation and generally do not
evoke an adverse foreign body reaction (i.e. tissue response) when implanted, their use
is limited by a number of disadvantages. Naturally derived polymers suffer from large
batch-to-batch variation in properties, possible contamination, poor mechanical
performance and most important, limited possibilities for processing (e.g., collagen and
chitin cannot be heat processed)15.
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Table 2. Methods to produce scaffolds for soft tissue regeneration.
Non-design controlled Design-controlled
Method Pros Cons Method Pros Cons







































































































































Ever since the introduction of (bio)degradable polyglycolic acid (PGA)-based surgical
sutures to the market in the 1970s18, the interest in degradable polymers for medical
purposes gained increasing interest. Scientific research in this field exponentially
increased and was mainly focused on the development of novel polymers as scaffolds for
various TERM applications for the last two decades. Investigated materials belonging to
the family of (bio)degradable polymers are contained in the Table 3. Due to the
robustness of the manufacturing process, the readily availability and FDA approved
monomers, degradable poly(-esters) obtained by the ring-opening polymerization
(ROP) of different lactones (e.g., glycolide, D,L-Lactide, L-Lactide, -caprolactone)
comprise the majority of the polymers considered for TERM applications. The ROP is
conventionally catalyzed by organo-metallic compounds (e.g., Stannous Octanoate). For
biomedical applications, the organo-metallic catalyst is seen as an impurity with possible
adverse effects due to suspected toxicity. In the last decade, an alternative has been
extensively sought in nature’s own catalysts, enzymes. Enzyme catalysis can be used to
produce a variety of polymers such as: carbohydrates (e.g., cellulose, amylase, xylan,
hybrid type polysaccharides), polyesters, polycarbonates and polyphosphates19-23. In
addition, enzyme catalysts can be employed for obtaining polymers that are impossible
or very difficult to prepare via conventional chemical catalysis, for instance in
regiospecific and enantioselective polymerizations19. Lipases (e.g., Candida antartica,
Candida rugosa, Pseudomonas cepacia, Rhizopus delemar, porcine pancreatic lipase) are
capable of catalyzing ROP of small and large ring lactones (macrolides), lactides and
cyclic carbonates regardless of the ring strain and chemical polymerizability19. The
unstrained γ-butyrolactone could not be polymerized using aluminoxane initiators but it
could be polymerized by enzymes such as lipases24-26. In addition to providing catalysts
that can be easily removed and synthesis of specialty polymers, enzymatic catalysis also
exhibits other advantages compared to the chemical catalysis such as: mild
polymerization conditions (i.e. lower temperature, atmospheric pressure), possibility of
conducting reactions in bulk, in organic media and at interfaces22 . Furthermore, lipases
do not require exclusion of water and air when producing polyesters.
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Table 3. Degradable biomedical polymers. Presented data adopted from Gunatillake et al.27,
Williams et al.28, Chen et al.9 and Nair et al.29.
A disadvantage of using poly(-esters) is the acidic degradation products build up within
the degradable polymer matrix30, 31. This results in the lowering of local pH and auto-
catalytic hydrolysis of the ester bond. Following the bulk erosion mechanism (see
section: “Degradation of biomedical polymers”), the acidic products are released in large
concentration which causes local inflammation at the implant site and therefore,
seriously hamper biocompatibility. Furthermore, PCL and PTMC are slowly degrading
polymers and are not suitable for TERM of soft tissues9, 29. The copolymerization with
other lactones can increase their degradability. However, the release of acid degradation
products is not avoided by copolymerization. Based on their possible application,
degradability and physical properties, the rest of polymer types listed in the Table 3 can
roughly be divided into polymers for typically orthopedic applications, polymers typically
utilized in drug delivery and the intermediate polymers that could be used in soft tissue
regeneration. Typical polymers for orthopedic applications are: crosslinked
poly(propylene fumarate), tyrosine-derived poly(amino acids) and polyphosphazanes.
The most appropriate polymers as drug delivery mediators are poly(ortho esters),
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polyanhydrides, poly(alkyl cyanoacrylate) and polyphosphoesters. Although very
attractive, synthetic polyaminoacids are usually obtained by multiple steps synthesis
under controlled conditions, which makes them laborious and expensive to produce,
especially in the quantities required for manufacturing of 3D-implants32.
Owning to their great potential in tailoring the polymer structure to achieve the desired
physio-chemical and mechanical properties, polyurethanes (PUs) hold great potential as
polymers for TERM of soft tissues. In addition to excellent mechanical properties, PUs
exhibit good blood compatibility. Last, but not the least, PUs can be processed using a
broad range of processing methods.
Degradation of biomedical polymers
Degradable polymers are materials that degrade within the duration of their application,
or immediately after it. All polymers degrade. Thus, so-called “non-degradable” polymers
are those materials that require substantially longer time to degrade than the duration of
their application. The terms degradation and erosion are being used interchangeably. In
its essence, degradation starts with polymer chain-scission, where functional groups of
the polymer are cleaved followed by the release of oligomers, and finally monomers. The
process of “erosion” represents the loss of polymer material due to loss of oligomers and
monomers from the degrading polymer matrix30. Polymer degradation can be classified
into: photo-, thermal-, mechanical and chemical. For biomedical applications, thermal
degradation is not of interest. Photo-degradation can start before the actual application,
as a result of UV- or γ-sterilization. During the application, mechanical and chemical
degradation are the most relevant. Mechanical degradation refers to the biomedical
polymers that are subjected to mechanical stresses, for instance sutures or internal
fixation devices, also called “wear” devices. Chemical degradation of biodegradable
polymers always occurs regardless of their application, and is therefore, considered the
most important degradation mechanism.
All biodegradable polymers are comprised of hydrolyzable functionalities which can
degrade unassisted or catalyzed by acidity of degradation products (autocatalysis)
and/or enzymes. The extent and the rate of the hydrolytical degradation depend on the
physico-chemical properties of the polymer matrix, such as chemical nature of the
degradable functionality and possible steric hindrance, degree of swelling, crystallinity,
object morphology and shape.
Polymer erosion depends on swelling, solubility of degraded species in water and their
diffusability through the polymer matrix and morphological changes induced by the
degradation30, 33. Based on the mechanism of erosion, biodegradable polymers are
divided into: surface eroding and bulk eroding33. Surface eroding polymers gradually lose
material from surface; during degradation the object becomes smaller, but maintains its
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shape and strength. In case of bulk eroding polymers, the chain-cleavage will not result
in the decrease in size of the object for a considerable time until channels are made from
the inside of the degrading matrix to the surface of the polymer. For most of the
applications, surface erosion is preferred above the bulk erosion, since the degraded
material is continuously removed from the surface in a linear, and therefore, predictable
manner. In addition, surface erosion prevents the accumulation of possibly harmful
concentrations of degradation products (e.g., acidic products during degradation of
poly(-esters)).
Polymer surface properties and cell adhesion
Biodegradable scaffolds designed for application in TERM of various damaged tissues
should be able to provide cell adhesion and proliferation. Cell adhesion to biomedical
polymers is mainly governed by the polymer surface properties, such as surface chemical
composition, roughness and hydrophobicity34-37. Therefore, it is essential to assess these
properties when designing biodegradable scaffolds. Cell adhesion and proliferation are
usually tested in vitro, by seeding bare or surface-modified biomaterials with a cell type
relevant for the application.
From the moment a cell suspension in culture medium is brought into contact with a
biomaterial, a sequence of events occurs. First, serum proteins (present in the fetal calf
serum, FCS, supplement of most culture media) adhere to the surface. Protein deposition
depends on the protein and biomaterial surface properties (e.g., hydrogen bonds,
hydrophobic interactions between the biomaterial and a protein). The protein adhesion is
a reversible process that includes attachment and detachment known as the Vroman
effect38. Second, cell adhesion occurs via cell adhesion receptor binding to the
recognition sites of the adhered protein. Subsequently, cells spread and generally start
to excrete ECM. If the in vitro microenvironment is appropriate in terms of ECM and
growth factors, the cells continue their normal life cycle by proliferating. Due to their
artificial nature, most of the biomedical polymers do not provide adequate cell adhesion.
It is shown that this drawback could be avoided by coating of biomaterials with
appropriate ECM proteins39.
Biocompatibility
Initially, biocompatibility of biomaterials was defined as a list of events that had to be
avoided, i.e. the biomaterial had to be non-toxic, non-immunogenic, non-thrombogenic,
non-carcinogenic etc. However, in the period from 1940s to 1980s it became obvious
that the response to the biomaterial depends on the implantation site, that instead of
being inert, biomaterial should specifically react with the host organism and that it
should even degrade for some applications. As the result of these findings, in 1987
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biocompatibility has been re-defined as “the ability of a material to perform with an
appropriate host response in a specific situation”40. This definition, laid down by Prof.
David F. Williams, was general and self-evident and could not practically help in
categorization of individual biomaterials as biocompatible or not. Since it became more
obvious that the biocompatibility of a particular material is intimately connected to its
function, the author of the old biocompatibility definition revised it using examples of
long-term implantable devices, intentionally degradable implantable devices,
intravascularly invasive short term medical devices and tissue engineering products40.
New proposed paradigms for biocompatibility of long term implantable devices and
scaffolds for tissue engineering are as follows:
For long term implantable device: “The biocompatibility of a long term implantable
medical device refers to the ability of the device to perform its intended function, with
the desired degree of incorporation in the host, without eliciting any undesirable local or
systematic effects in that host”.
For tissue engineering scaffolds: “The biocompatibility of a scaffold or matrix for tissue
engineering product refers to the ability to perform as a substrate that will support the
appropriate cellular activity, including the facilitation of molecular and mechanical
signaling systems, in order to optimize tissue regeneration, without eliciting any
undesirable local or systematic responses in the eventual host”.
Finally, the revised definition of biocompatibility proposed in the year 2008 is as follows:
“Biocompatibility refers to the ability of a biomaterial to perform its desired function with
respect to a medical therapy, without eliciting any undesirable local or systematic effects
in the recipient or beneficiary of that therapy, but generating the most appropriate
beneficial cellular or tissue response in that specific situation, and optimizing the clinically
relevant performance of that therapy”40.
According to this new definition, the biocompatibility of a material can only be assessed
by implantation of the biomaterial shaped up as a final product ready for its intended
use. Since the development of an implant from the choice of the chemical structure to
authorities-approved medical device ready for clinic often takes more then 10 years, it
seems that recently proposed definition cannot fully be used in all product development
stages. This definition only applies to the biocompatibility assessment of the final clinical
product evaluated as therapeutic efficacy in patients.
During the last six decades a number of in vitro and in vivo tests have been developed
and performed to assess the biocompatibility of biomaterials.
Biocompatibility is evaluated by in vitro assays and in vivo implantation experiments.
Although the biomaterials are developed to be used in vivo, the complexity of in vivo
reactions often makes interpretation of results difficult. In addition, using cell cultures
i.e. in vitro is more economical and, some might argue, more ethical then animal
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experimentation. It is recommendable to use cells of human origin, primary or stable
(immortalized) cell lines. The advantage of using cell lines is that they exhibit more
constant phenotype as opposed the primary cell cultures that are by definition
heterogeneous. The disadvantage is they frequently lack one or more features typical for
their in vivo counterparts. When studying cell behavior on biomaterials, regardless of a
cell type or the final biomaterial application, it is of interest to assess: cell adhesion,
proliferation and function41. Cell adhesion is a process in which specific cell surface
receptors recognize binding domains of proteins adsorbed on the biomaterial surface.
Once adhered, cells undergo further cytoskeletal changes, resulting in cell spreading and
migration on the biomaterial surface. One of the properties of viable cells is proliferation,
and it is therefore important to investigate. Cell adhesion is measured by simple
enumeration of adhered cells (DAPI, DNA extraction, light microscopy among others).
Cell proliferation can be monitored by immuno-detection of incorporated
bromodeoxyuridine (BrdU) into DNA or by assessing the expression of the nuclear
marker Ki-67 to mention a few.
The final evaluation of the biomaterial tested for biocompatibility should be performed in
vivo. The experimental procedure varies between researchers which complicates
comparison of the results. There are several factors that influence the course and fate of
the implant in animals: species of the test animal, age of the animal, implantation site,
duration of the experiment and implant characteristics (implant shape and size, surface
morphology, hydrophobicity and roughness)42. Evaluation starts after explantation: the
tissue is placed in a fixative, dehydrated in graded alcohol solutions and subsequently
embedded in paraffin of plastic. The embedded tissue is then sliced into thin sections,
stained (with e.g., hematoxylin) and mounted on slides. The tissue response or foreign
body reaction (FBR) is assessed by light microscopy methods. Further investigation into
type and function of cellular tissue constituents (e.g., macrophages, giant cells,
fibroblasts, vascular endothelium, collagen) is done by immunohistochemical analysis.
This method requires for the explanted tissue to be snap-frozen at - 70°C and cut in thin
sections. The sample is further treated with an appropriate enzyme substrate. Although
still far from the clinical situation, studies of biocompatibility of biomaterials using an
animal model provide information on the extent and mechanism of the tissue response
that the tested biomaterial evokes (foreign body reaction). Furthermore, animal studies
are essential to assess biomaterial degradation in vivo.
Foreign body reaction (FBR) to biomaterials
Foreign body reaction (FBR) to biomaterials is a complex response mechanism that
proceeds via a sequence of events defined as: injury, blood-material interactions,
provisional matrix formation, onset (acute inflammation), progression (chronic
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inflammation), granulation tissue development, foreign body giant cell formation, and
resolution via fibrosis/fibrous capsule development43, 44 (Fig. 2). In general, the FBR
comprises of three stages: onset, progression and resolution45
Figure 2. Sequence of events characteristic for FBR to biomaterials (adopted from Anderson et
al.44
Table 4 provides an overview of the cell types and ECM elements involved in the FBR to
biomaterials. Not all the cell types play a role throughout the FBR process. For instance,
even though neutrophils are recruited first, they are replaced relatively fast by
monocytes which differentiate into macrophages.
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The initial inflammation response is triggered by injury caused during the implantation of
a biomaterial. Because of the invasion on vascularized connective tissue during the
surgical procedure, the material contacts with blood and almost immediately acquires a
protein layer, so-called provisional matrix43. This initial protein deposition (protein type
and conformation) depends on the surface properties of the biomaterial (i.e. chemical
composition, hydrophobicity, roughness). The adsorbed protein layer comprises
mitogens, chemo-attractants, cytokines, growth factors and other bioactive agents that
dictate adhesion and survival of monocytes, macrophages and foreign body giant cells
(FBGCs). The injury also leads to thrombin formation involving activation of the extrinsic
and intrinsic coagulation systems (see section: “Haemocompatibility”), the complement
system (see section: “Haemocompatibility”), the fibrinolytic system, the kinin-generating
system and platelets46-48.
The onset (acute inflammation) lasts relatively short (from minutes to days) and is
characterized by neutrophils (polymorphonuclear leukocytes; PMNs) modulated by
histamine release and fibrinogen adsorption. The major role of neutrophils in this stage
of FBR is to phagocytose microorganisms and foreign materials. Furthermore, they
secrete chemokines that attract monocytes. Due to the size discrepancy between the
Chapter 1
22
biomaterial and neutrophils, instead of real phagocytosis, a so-called “frustrated
phagocytosis” occurs43. Although the degradation of the biomaterial by PMNs is
inefficient, activated PMNs secrete a host of degrading enzymes, including proteases.
Chronic inflammation is characterized by presence of macrophages, monocytes and
lymphocytes. At this stage, proliferation of blood vessels and connective tissue is also
observed. Due to the number of active biologicals (enzymes, growth factors,
cyt/chemokines and more) they produce, macrophages are the most important cell type
and thus dominate the chronic inflammation phase. Macrophages are long-living cells
and are considered key mediators in the development of immune reactions. They
produce a large spectrum of factors, to mention only a few: proteases, chemotactic
factors, reactive oxygen metabolites, complement components, coagulation factors,
growth-promoting factors and cytokines44.
Proliferation of newly formed small blood vessels and fibroblasts active in producing
collagen and proteoglycans leads to formation of the granulation tissue. The molecular
composition of the granulation tissue changes from predominately proteoglycan to
collagen III.
To further facilitate the phagocytosis of the biomaterial, macrophages fuse to form
foreign body giant cells (FBGCs). The exact molecular mechanism that leads to the
fusion of macrophages into FBGC has not been fully described44. However, two key
factors have been defined: necessity of appropriate fusion inducing stimuli (e.g., IL-4,
IL-13, MCP-I) and protein composition adsorbed onto the implant surface (e.g.,
fibronectin, vitronectin). Generally, more rough surfaces (e.g., fabric or porous materials)
lead to localization of larger number of FBGCs and macrophages at the implant surface.
As well as the macrophages, FBGCs also produce a range of degradation mediators49, 50.
It has been shown that adherent macrophages and FBGCs contributed to the
degradation of Pellethane 2363-80A® (a polyurethane) via the environmental stress
cracking (ESC)51, 52. Furthermore, FBGC are recognized as potential immune response
regulator of the FBR53.
Haemocompatibility
Regardless of the biomaterials final application, i.e. blood-contacting (e.g., vascular
prosthesis, heart valves) or not, haemocompatibility of any new biomaterial should be
addressed. However, the standard experimental set on how to assess biomaterials
haemocompatibility does not exist. The lack of standardization hampers the comparison
of results obtained by different research groups.
The cell and molecular biology of blood activation and coagulation is extremely complex.
From the moment biomaterial comes in contact with blood (during implantation),
coagulation and complement systems are activated and cause an inflammatory reaction
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(the onset of the FBR). These three processes are interrelated and are dictated by
interaction of the main players i.e. proteins, platelets, neutrophils, macrophages and
FBGCs44, 46. Due to the complexity, these events are investigated separately.
The coagulation cascade can be divided into an intrinsic system and an extrinsic system46
(Fig. 3). The intrinsic system is activated by the contact of blood with the biomaterial,
while the extrinsic system is triggered by tissue factor (TF) secreted by damaged cells at
the site of vascular injury. Most of the methods to study the coagulation of biomaterials
focus on the intrinsic system activation and resulting generation of either thrombin and
fibrin.
Figure 3. Coagulation cascade. Taken from Gorbet et al46.
The complement system consists of approximately 30 plasma and membrane-bound
proteins. The role of the complement system is to destroy and remove substances, either
by direct lysis or by mediating the leukocyte function in inflammation and innate
immunity. The complement system is triggered by an enzyme that catalysis the
formation of C3 convertase, which further causes C5 convertase formation and the final
assembly, terminal complement complex (TCC)46 (Fig. 4). TCC inserts into the lipid layer
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of the target cell, resulting its damage and/or lysis. In the case of the biomaterial, TCC
binds to the deposited protein layer (i.e. vitronectin). During complement activation,
several peptides are released, such as C3a, C4a and C5a that are capable of binding to
specific receptors on neutrophils, monocytes, macrophages, mast cells and smooth
muscle cells (SMC) and can lead to their activation. Furthermore, these peptides
influence chemotaxis, vasodilatation and cell attachment46.
Figure 4. Complement activation mechanism. Taken from Gorbet et al46.
Polyurethanes
Owning to a wide range of physical and chemical properties, polyurethanes (PUs) found
numerous applications in everyday life, covering a broad range of products, e.g.,
coatings, insulation foams and high impact engineering plastics. Polyurethanes are
synthesized via an addition reaction between a diol and a diisocyanate, leading to the
formation of the urethane bond (Fig. 5). Depending on the stoichiometry of the
reactants and the alcohol functionality, PUs can be thermoplastic elastomers or
covalently cross-linked thermosets. Covalently cross-linked PUs are employed in the
manufacturing of insulation materials (soft or rigid PU foams) and protective coatings.
These PUs, being thermosets, cannot be further processed (dissolved or molten), and
are therefore not very appealing for the development of biodegradable scaffolds.
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Figure 5. Formation of the urethane bond.
Thermoplastic PUs are segmented structures comprised of defined blocks of so-called
“soft” (oligodiol) and “hard” segments (diisocyanate and chain-extender) which result in
the phase-separated morphology54, 55. Due to the vast variety of choices for both “soft”
and “hard” segment, there are numerous different combinations leading to the polymers
with different properties. The soft segment is usually comprised of hydroxyl-terminated
polyesters, polyethers or polycarbonates in the amorphous phase. The diisocyanate can
contain an aromatic or an aliphatic moiety. The hard segment is rarely solely based on a
diisocyanate. Usually, to achieve good mechanical properties a chain-extender has to be
used, the most common being aliphatic difunctional alcohols and difunctional amines.
The hard segment is capable of forming hydrogen bonds as depicted in the Fig. 6.
Figure 6. Formation of H-bonds in polyurethanes. a) H-bonds between two urethane groups, b)
H-bond between urethane and ester.
Soft and hard segments are preferably physically incompatible, creating a microphase-
separated morphology, where hydrogen-bonded hard segment forms physically cross-
linked crystals dispersed in the soft segment matrix (Fig. 7). The existence of the
microphase separation (MS) is essential for good mechanical properties of segmented
PUs. Hydrogen bond (H-bond) interactions between urethane segments (Fig. 6a)
contribute to the MS and thus mechanical properties, whilst H-bond formation between
the urethane and the ester bond lead to phase mixing (Fig. 6b).
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Figure 7. Schematic representation of the microphase separation of polyurethanes. a –
amorphous mixture of hard and soft segments; b – crystalline hard segment domains; c –
paracrystalline soft segment; d – disordered soft segment; e – disordered hard segment56
Due to their chemical nature, hard segments are generally more hydrophilic than the
oligodiol soft segments. Since most of the biomedical polyurethanes are above their
glass transition temperature (Tg) during application, the above-mentioned segments are
relatively mobile. It is shown that the surface of PUs contacting hydrophobic air
predominantly comprises of soft segment55. Upon immersion of PU in a humid
environment, the hard segments arise to the surface57 (Fig. 7). This dynamic nature of
PUs can be utilized when designing scaffolds for regeneration of soft tissues.
Figure 8. Dynamic surface properties of polyurethanes.
Biomedical polyurethanes
As mentioned, PUs have been extensively investigated as materials for biomedical
devices58. The initial interest included only biostable PUs predominantly in blood-
contacting device applications. Avcothane®, Biomer®, Pellethane® and Tecoflex® are all
poly(ether urethanes) based on the poly(tetramethylene oxide) (PTMO)52. Although
these materials appeared biocompatible and biostable, it was shown that they do
degrade in vivo by biologically assisted environmental stress cracking (ESC) and metal
ion-supported oxidation leading to calcification51. Furthermore, when the extracts during
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the degradation of Pellethane® were analyzed, 4,4’-butane dianiline (MDA) was detected.
MDA is a known carcinogen, mutagen and displays immediate cell toxicity. To circumvent
the problems of ESC and toxicity, biomedical polyurethanes based on totally
hydrogenated version of the 4,4’-butane diphenylisocyanate (MDI), 1,4-cyclohexane
diisocyanate (HMDI) and various polycarbonate soft segments have been developed
(e.g., Corethane™)52, 55.
Considered not applicable for medical devices at first, poly(ester urethanes) received
more attention in the last two decades since researchers started exploiting their
degradability. Degradation of poly(ester urethanes) proceeds predominantly via
hydrolytic cleavage of the ester bonds of the ester oligodiol. In addition to the variety of
degradable polyester oligodiols, new aliphatic diisocyanates were developed, for instance
hexamethylene diisocyanate (HDI) 1,4-butanediisocyanate (BDI) and lysine diisocyanate
(LDI)54. The use of aliphatic instead of aromatic diisocyanates generally results in lesser
mechanical properties due to the lower degree of MS which limits their application for
load bearing applications. However, aliphatic diisocyanate-based PUs should be suitable
for soft tissue regeneration. Upon degradation, BDI and LDI convert to the
corresponding diamines that are naturally occurring substances in the body and are
therefore considered safe to use in vivo.
For hard tissue function restoration like meniscus replacement, polyurethane (PU) foams
based on poly(ε-caprolactone) (PCL) and BDI have been developed in our laboratory59.
Foams were prepared by combined method of salt leaching and thermally induced phase
separation. The implanted PU foams had a completely interconnected pore structure,
caused only mild inflammatory reaction, and were completely filled with extracellular
matrix and cells of cartilaginous phenotype after 3 month’s of implantation in dogs60.
However, similar foams of the same PU were still not fully degraded 2 years after
implantation61. Slow degradability might be an obstacle to healthy tissue regeneration
when support is needed for a shorter time by causing a prolonged FBR. The
development of novel PUs with a tunable degradation time and pattern is a formidable
challenge. Yet, a property “tuned” PU would favor adequate tissue regeneration without
an adverse course of the FBR. In order to improve the MS and enhance degradability of
PUs with PCL-based soft segments, Heijkants et al. introduced terephthaloyl diisocyanate
(TPHDI)62, 63. The acyl functionality contributes to the greater reactivity of TPHDI and is
expected to hydrolyze relatively fast.
Outline of the thesis
The aim of this thesis was to design haemocompatible polyurethane scaffolds for soft
tissue regeneration that would gradually degrade faster than the commercially available
segmented polyester urethanes evoking only mild tissue response. In exploring
Chapter 1
28
possibilities of applying polyurethanes as degradable scaffolds, we focused on three
essential aspects of application of biomaterials in the regeneration of soft tissues:
hydrolytic degradation, scaffold design and biocompatibility assessment in vitro and in
vivo.
First we studied the hydrolytic degradation of novel polyurethanes, polyacylurethanes
(PAUs) with the accent on microphase separation change during the course of the
degradation (Chapter 2). The potential to use PAUs as scaffolds for tissue engineering
was further investigated by assessing cell adhesion and haemocompatibility of these
materials in vitro (Chapter 3).
To enhance the degradation rate of poly(ε-caprolactone)- and 1,4-butanediisocyanate-
containing polyurethanes, slowly degrading poly(ε-caprolactone) oligodiol has been
replaced by copolymers comprising of ε-caprolactone and γ-butyrolactone (Chapter 4).
Since γ-butyrolactone does not polymerize efficiently via conventional synthetic
pathways, the copolymers were obtained by enzyme-catalysis. The aim of the
subsequent study was to develop and evaluate biodegradable and haemocompatible
scaffolds utilizing these novel polyurethanes. The scaffolds were characterized by
interconnected-pore morphology that was expected to provide gradual and mild tissue
remodeling at the implant site (Chapter 5).
Finally, the results described in this thesis are summarized and future perspectives are
discussed (Chapter 6).
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Polycaprolactone (PCL) polyester and segmented aliphatic polyester urethanes based on
PCL soft segment have been thoroughly investigated as biodegradable scaffolds for
tissue engineering. Although proven beneficial as long term implants, these materials
degrade very slowly and are therefore not suitable in applications in which scaffold
support is needed for a shorter time. A recently developed class of polyacylurethanes
(PAUs) is expected to fulfill such requirements. Our aim was to assess in vitro the
degradation of PAUs and assess their suitability as temporary scaffold materials to
support soft tissue repair.
With both mass loss of 2.7 – 4.0 % and decrease in molar mass of approx. 35 % over a
period of 80 days, PAUs were shown to degrade via both bulk and surface erosion
mechanisms. A pseudo-first order autocatalytic reaction model expressed through a
pseudo-first order reaction could not describe the PAUs hydrolysis adequately. Instead,
the molar mass of PAUs in the course of degradation was fitted better assuming a first
order exponential decay function. Fourier Transform Infra Red (FTIR) spectroscopy was
successfully applied to study the extent of PAUs microphase separation during in vitro
degradation. Due to predominant chain scission at the surface and increased chain
mobility, the content of the crystalline soft and hard segment phases was higher at the
surface in comparison to the bulk. Although surface roughness increased with
degradation, the contact angle decreased, indicating that the surface of PAUs had
become more hydrophilic. The latter is expected to render PAUs more cell-adhesive.
Due to its optimal in vitro behavior, PAU1000 (molar mass of the oligocaprolactone soft
segment = 1000 g/mol) can be recommended as a potential scaffold material to be used
in regenerative medicine.
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1. Introduction
Degradable polymers are preferred candidates for designing therapeutic devices to treat
missing or damaged soft tissues. Being FDA approved, polycaprolactone (PCL) has been
intensively investigated as temporary scaffold biomaterial. However, PCL suffers from
significant drawbacks. PCL is found to degrade very slowly both in vitro and in vivo, with
almost no mass loss and decrease in molar mass for at least 6 months of degradation1, 2.
In addition, in order to achieve good mechanical properties, the molar mass of PCL has
to be relatively high which leads to an increase in crystalline fraction of this semi-
crystalline polyester. The latter might cause an obstacle for healthy regeneration in vivo3,
4.
Our aim was to develop a biomaterial with tunable (degradation) properties to serve as
temporary support in soft tissue regeneration.
Polyurethanes possess good mechanical properties and blood compatibility, which have
made them attractive for their use for manufacture of biomedical devices5. The
possibility to alter their mechanical properties by changing the ratio between the
constituent components, so-called soft segments (polyether, polyester, and
polycarbonate) and hard segments (aliphatic or aromatic diisocyanates), renders them
very useful in a variety of materials with different requirements.
To the best of our knowledge Endo et al.6 have described polyacylurethanes in literature
for the first time in 1994. The polymers were prepared by the polyaddition of bis(N-acyl
isocyanates) with low molecular weight diols and polyether diols. The most interesting
feature of this polymerization was the high reactivity under mild conditions of the bis(N-
acyl isocyanates) towards the polyether diols without the use of additional catalysts.
In a patent of 1995 Yabuta and Urano claimed the preparation of polyacylurethanes
where the diol could be a polycaprolactone prepolymer, introducing this class of
polymers in the area of thermoplastic elastomers7. However, the procedure described
involved quite high temperatures and long reaction times and resulted “preferably” in
rather low molar mass polymers. Apparently also preferred was the use of self-
condensing unsymmetrical monomers containing only one acylisocyanate group. The
polymers have been characterized as easy-degradable.
Recently, polyacylurethanes (PAUs) have been developed in our laboratory8, 9. These
materials were produced without the use of any toxic catalysts of which remnants might
limit biomedical use. Polyacylurethanes are synthesized with terephthaloyl diisocyanate
(TPHDI), which is expected not only to enhance materials mechanical properties due to
improved micro-phase separation10, but is also expected to result in non-toxic
degradation products11. The acyl functionality contributes to the greater reactivity of
TPHDI12 and is expected to hydrolyze relatively fast13.
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The goal of this research was to assess the hydrolytical degradation of PAUs, with an
accent on the mechanism of PAU hydrolysis and microphase separation. Describing the
degradation of PAUs in vitro will be used as a starting point to explain its in vivo
behavior.
In this study, we show the results of the degradation study of PAUs with different
lengths of the oligo(ε-caprolactone) soft segments (Number average molar mass =
1000, 1500 and 2000 g/mol, PDI = 1.69, 1.82 and 1.90, respectively). PAU
characterization included monitoring mass loss, molar masses, and thermal and surface
properties of PAUs upon a degradation period of 80 days. The microphase separation of
PAUs was analyzed by utilizing Fourier Transform Infra Red (FTIR) spectroscopy.
2. Materials and Methods
2.1. Materials
ε-Caprolactone (CL) was obtained from Union Carbide (Terneuzen, The Netherlands) and 
was purified by distillation under reduced pressure from calcium hydride (CaH2).
Terephthaloyl diisocyanate was synthesized from terephthalamide, obtained from TCI
(Japan) and oxalyl chloride from Sigma-Aldrich (Zwijndrecht, The Netherlands) using a
modified method of Tsuge et al14. Analytical grade 1,4-butanediol (BDO) was purchased
from Sigma-Aldrich (Zwijndrecht, The Netherlands) and purified by distillation from 3 Å
mole sieves under reduced pressure. Chloroform, diethyl ether, dimethyl formamide and
n-hexane as analytical grade solvents were purchased from Acros Organics (Geel,
Belgium) and were used without further purification. Sodium azide was purchased from
Sigma-Aldrich (Zwijndrecht, The Netherlands) and used as received.
Polyacylurethane films were cast from chloroform onto PFA Petri dishes (perfluoroalkoxy
polymer resin) obtained from Bergof (Florida, USA).
2.2. Synthesis of polyacylurethanes
Polyacylurethanes (PAUs) were synthesized by a slightly modified method of Heijkants et
al.8. The synthesis was performed in two steps: 1) oligodiol synthesis and 2)
polymerization of the oligodiol with terephthaloyl diisocyanate (TPHDI). The oligodiols,
poly(ε-caprolactone) (PCL) diols of three different lengths (1000, 1500 and 2000 g/mol)
were prepared by thermal polymerization employing 1,4-butanediol as an initiator
without the use of any catalyst at 150°C for 7 days under argone15. The second step was
performed in the Micro Twin Extruder. Briefly, a powder mixture of PCL (molar mass =
1000 g/mol) (approximately 7.0 g; 7.0 mmol) and TPHDI (0.75 g; 3.5 mmol) was fed to
a micro-extruder at 65°C. Subsequently, the extruder was heated up to 130°C and
another portion of TPHDI (0.75 g) was added. The average polymerization time was 6
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minutes; the resulting polymer was collected, purified by precipitation in diethyl ether
from chloroform solution, and dried in a vacuum stove at 40°C. The reaction scheme is
depicted in Fig. 1.
Figure 1. Synthesis of polyacylurethanes. Terephthaloyl diisocyanate (TPHDI) and poly(ε-
caprolactone) (PCL) are reacted without a catalyst to yield polyacylurethane (PAU).
2.3. Preparation of polymer films
Polymer films were prepared by casting a 2 w/v % polyurethane solution in chloroform
onto ID 8 cm PFA Petri dishes at room temperature. The films were washed in a Soxhlet
apparatus utilizing n-hexane as the extraction solvent in order to remove any surface
contaminants such as potentially present silicones. Finally, the materials were dried and
stored in the vacuum stove at 40°C until further use.
2.4. In vitro degradation set-up
Films obtained as described above were cut in quarters and weighed. Subsequently,
each piece was placed in a glass container and 100 mL of phosphate buffer (solution in
water, pH = 7.2; Sigma-Aldrich, Zwijndrecht, The Netherlands) solution, containing 0.02
wt% of sodium azide, was added. Labeled and well closed containers were placed in a
dark water bath at 37°C. At predetermined time points, starting from 5 up to 80 days,
samples (n = 2 per time point) were taken and rinsed with distilled water and blotted
gently with tissue paper to remove surface water. Subsequently, the samples were dried
in a vacuum oven at 40°C. The weight was monitored until it reached a constant value.
2.5. Mass loss
The mass loss of PAU-films upon in vitro degradation was determined by weighing the












Where mo is the dry mass before incubation and md is the dry mass after degradation.
2.6. Molar mass
The molar masses of the PAUs after synthesis and purification, as well as the molar
masses of samples (n = 2 films per time point) upon degradation were determined by
gel permeation chromatography (GPC) utilizing a Waters 600 Powerline system,
equipped with 2 mixed-C Pl-gel 5μ columns employing dimethyl formamide (DMF) with 
0.01M LiBr as eluens at 70°C. The data analysis was done using conventional calibration
with polystyrene standards accompanied by in-house software. Number average molar
mass (Mn) data (average of two samples per time point) were fitted by using the
OriginPro 7.5 software.
2.7. Thermal properties of PAUs
Thermal properties of PAUs as polymerized and at different time points of degradation
were measured with a differential scanning calorimeter Q 1000 from TA Instruments.
The samples with masses varying between 7 - 10 mg were heated from -85°C to +
150°C with a rate of 10°C/min. The data collected during the first heating run were
analyzed utilizing the TA Instruments software version 4.0.
2.8. Fourier-Transform Infra Red spectroscopy (FTIR)
All the infrared spectral manipulation was performed using the Opus v.4.2 software
package (Bruker Optik GmbH).
2.8.1. Transmission FTIR
Infrared transmission measurements were done on films cast on KBr pellets from
chloroform solution using a Bruker IFS88 spectrometer equipped with a MCT-A detector
at the resolution of 2 cm-1. The KBr pellets were measured horizontally using the Bruker
infrared microscope accessory. Five hundred scans were recorded per spectrum.
Temperature was varied from room temperature to 120°C.
2.8.2. Deconvolution of the carbonyl region
The carbonyl absorption region from 1850 cm-1 to 1575 cm-1 was deconvoluted by fixing
the peak position and allowing for peak intensity, width and shape to be optimized by
the Opus software. The Levenberg-Marquardt algorithm was used in curve fit
optimization. The calculated residual RSM fitting error was always < 0.009.




ATR-FTIR was done using a Bruker IFS88 spectrometer equipped with a Golden Gate
(Graseby Specac) single reflection ATR accessory. Spectral resolution was 4 cm-1 and 50
scans were taken per spectrum. The percentage of the soft and the hard segment
crystallinity was calculated as explained in 2.8.2.
2.9.2. Contact angle measurements
The surface properties of PAU1000 and PAU2000 were assessed during the in vitro
degradation. At predetermined incubation times, the samples were rinsed by means of
spraying distilled water against both sides of the samples. The samples were blotted with
tissue paper, the film was fixed to glass slides by double-sided adhesive tape and the
contact angle was measured using a sessile drop method using a Krüss Drop Shape
Analysis System DSA 10.
3. Results and Discussion
3.1. Mass loss and molar mass change
Polyester urethanes are believed to undergo hydrolytic degradation via two different
mechanisms identified as bulk degradation and surface erosion16, 17. Bulk degradation is
characterized by an overall decrease of molar mass if random chain scission is occurring.
Surface erosion is the process where hydrolysis removes only polymeric chains from the
outer layer of the material and this leaves the bulk of the material untouched16. Surface
erosion is favored for many applications of polymeric biomaterials (e.g. controlled drug
delivery), because the material properties remain virtually intact since degradation
proceeds through removal of very thin layers of the material.
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Figure 2. Mass loss of PAU films with different soft segment length’s at 37°C in phosphate buffer
(pH=7.2). (○) PAU1000, (■) PAU1500 and (▼) PAU2000.
For all three PAUs mass loss showed a similar pattern, with 2.7 - 4.0 wt% decrease in
mass at the final time point (Fig. 2), which is relatively high. Especially when compared
to other PCL-based materials that are intended for similar applications and which show
almost no mass loss even for more than a year1, 18. The apparent high mass loss at the
first incubation time point (5 days) can be attributed to different sample manipulation of
the incubation samples compared to the non-incubated samples. During preparations for
the degradation study (as previously described) prior to weighing, samples were exposed
to air and thus may have absorbed water. Therefore, by calculating the linear fit, we
only compared the mass loss trends of the three PAUs and calculated the mass loss at
the end of the examination period (day 80). Since the potential impurities and residual
non-reacted material were removed by means of Soxhlet extraction with n-hexane, the
observed mass loss upon incubation can only be ascribed to PAU degradation. The PAU
films changed from flexible to brittle and fragile with the course of degradation (Fig. 2).
The degradation was accompanied by molar mass decrease, indicating that chain
scission in bulk had occurred additionally. The molar mass of degraded PAUs decreased
approximately 32 % for PAU1000 and PAU1500, to 38 % for PAU2000 compared to the
non-degraded samples (data not shown). It is generally believed that in vitro
degradation of polyester urethanes proceeds via autocatalytic scission of the ester bond
of the polyester soft segment. Pitt et al.19 derived the following equation to describe the
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or in its linearized form:
0
n nln( M ) ln( M ) k t  
where Mn [gmol-1] is the number
average molar mass of the polymer
at any time point, Mn0 is the initial
number average molar mass [gmol-
1], k is the ester hydrolysis rate
constant [day-1] and t is the
degradation time [day]. If we
assume that the above described
model is applicable for PAU
degradation, then values of ln(Mn0)
of PAUs as a function of t can be
described by a linear function (Fig.
3).
Figure 3. Decrease of PAUs molar mass in the course of hydrolytic degradation. Data set for PCL-
PUs was calculated assuming the same Mn0 and oligodiol molar mass of corresponding PAUs and
hydrolysis rate constant (k) value for PCL-PUs as given by Heijkants et al18.
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However, when fit parameters were analyzed, r2 value for PAU1000 and PAU1500 fit
were ~ 0.6 which indicated a poor fit.
This indicated that the PAU degradation proceeded not only via scission of ester bonds of
the PCL soft segment. Water can attack the following functional groups: ester groups of
the soft segments, acyl groups of the hard segments and urethane groups of the hard
segments (Fig. 4). As a result aliphatic carboxylic acids, aromatic carboxylic acids,
aliphatic alcohols and primary amides can be formed. Both hydrolysis of the soft
segment esters and acyl urethane groups are acid catalyzed and expected to contribute
greatly to PAU degradation.
Figure 4. Hard segment hydrolysis.
Fitting the PAUs Mn data using a first order exponential decay model corresponded better
with the experimental data as confirmed by r2 values (fitting parameters not shown).
Using a first order exponential model resulted in the following equation to describe
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The observed deviation of the proposed pseudo-linear autocatalytic model and
degradation of PAUs originates from the fact that the basic assumptions for this model
were not fulfilled. The autocatalytic model was derived based on the following
assumptions: 1) extent of chain scission is small, 2) only ester bonds hydrolyze and 3)
there is no mass loss19. PAUs did loose mass and in addition to the ester groups of the
soft segment, acylurethane groups also might hydrolyze. Even though they were both
composed of the same molar mass of the PCL soft segment, PAUs degraded much faster
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than PCL-PUs based on a BDI hard segment18 (Fig. 3). This can be explained by the
chemical nature of the acylurethane moiety and the lower degree of microphase
separation of PAUs compared to the PCL-PUs (see section 3.2 for details).
The combination of mass loss and decrease of molar mass indicates that the hydrolytic
degradation of PAUs occurs with combined bulk and surface erosion mechanisms.
3.2. Thermal properties of PAUs upon degradation
Three PAUs with different PCL-oligodiol molar masses (PAU1000, PAU1500 and
PAU2000) exhibited different melting endotherms (Fig. 5).
Figure 5. Thermal properties of PAUs upon degradation at 37°C in phosphate buffer solution (pH
= 7.2). Heating endotherms (1st heating scan) of PAUs with different PCL-oligodiol lengths non-
degraded (0 days) and at the end of the degradation period (80 days). Tg – glass transition
temperature; Tm,,SS – soft segment melting temperature; Tm,HS – hard segment melting
temperature.
Analysis of the PAUs before the in vitro degradation revealed a microphase separated
structure in the case of PAU1000 and PAU1500, characterized by a hard segment melting
peak and the glass transition temperature (Tg) of the soft segment (Fig. 5). PAU2000
was not microphase separated, showing only a melting peak originating from crystalline
PCL-soft segment, indicating that the preferred mechanical properties typical for
polyurethanes were virtually absent.
Both PAU1500 and PAU2000 contained a relatively high fraction of crystalline PCL-soft
segment (no Tg detectable of the soft segment of PAU2000) which could retard the
hydrolytic degradation both in vitro and in vivo. The appearance of the soft segment
melting peak in PAU1000 from day 50 (Fig. 5 & 6) on is a result of the chain scission and
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increased mobility of PCL-soft segments. Similar results have been observed earlier by
different research groups1, 2, 20.
Figure 6. Soft segment and hard segment melt enthalpies of PAUs upon degradation. A: Soft
segment melt enthalpy (ΔHm,SS), B: Hard segment melt enthalpy (ΔHm,HS).
However, the amount of crystalline PCL even after 80 days of degradation was negligible
(Fig. 6A) and it was not expected to influence PAU1000 degradation to a great extent.
The soft segment crystallinity of PAU2000 gradually increased with incubation, most
probably because some chain scission had occurred in the amorphous phase of the
PAU2000, allowing for higher chain mobility. In addition, the overall mobility of the
chains might have been facilitated by the long incubation (annealing) in the humid
environment at 37°C.
PAU1000 exhibited the highest (bulk) hard segment crystallinity (Fig. 6B), which
remained constant during the course of degradation.
3.3. Microphase separation of PAUs prior to degradation (trans-FTIR)
Since hydrolytic degradation can only take place in the amorphous fraction of the
polymer, the degree of microphase separation is one of the key factors that determine
the hydrolysis rate of segmented polyester urethanes. To be able to determine which
fraction of the hard segment is crystalline from the total urethane present (as a measure
of the extent of the microphase separation), an enthalpy of melting of the 100 %
crystalline hard segment should be known. Since this was not the case, we attempted to
calculate the extent of the microphase separation from the FTIR deconvolution analysis
of the carbonyl absorption region of the PAUs. The carbonyl region was found to be
suitable for this determination as described by Pretsch et al.21. Since only PAU1000 and
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PAU1500 exhibited microphase separation, PAU2000 was excluded from the FTIR
analysis.
Bearing in mind that H-bond associated C=O always appears at the lower
wavenumbers21, 22, and correlating the deconvolution results with the DSC observations
(Fig. 6), overlapping peaks in the C=O region were assigned as denoted in the Fig. 7. As
already known from literature, upon heating, dissociation of H-bonding occurs, followed
by the disorder of the hard segment (HS) and soft and hard segment mixing23, 24. The
disruption of the HS crystallinity led to the decrease in the crystalline HS peak in both
PAU1000 and PAU2000 (Fig. 7). The decrease of the HS crystallinity was accompanied
by the increase of the amorphous HS portion (Fig. 7). As already observed by DSC,
PAU1000 did not contain PCL soft segment (SS) in the crystalline form. The SS
crystallinity of PAU1500 decreased upon heating, which resulted in the majority of the SS
to be amorphous (Fig. 7).
Figure 7. Carbonyl region of PAUs (transmission FTIR) prior to degradation. A) Assignment of
peaks of the PAU1000 carbonyl region curve fit, B) PAU1000 – integral values of peaks with
temperature increase, C) PAU15000 – integral values of peaks with temperature increase.
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If we observe the molecular structure of the PAUs, we could suspect that the acyl
carbonyls and the phenyl ring could engage in a resonance interaction, which would
further result in coplanar intermolecular orientation and four different conformations
(two cis and two trans). Acyl carbonyls would than rotate relatively freely around the
single bond and the differences in the levels of vibration energies specific for the
different conformers would be small. However, if such a system gets fixed in any way,
the difference in energy levels of the conformers would become larger, which would
result in the splitting of the acyl carbonyl band. Sun et al. observed this phenomenon by
analyzing chemically similar polymers, poly[di(butyl) vinylterephthalate] (PDBVT)25. Due
to the attachment of the phenyl ring to a polyvinyl backbone, the energy levels became
further apart, leading to acyl carbonyl band splitting25.
The acyl carbonyl group of the PAUs is located next to the urethane bond, and
participates in the hydrogen bonding (H-bonding) of the HS. Since H-bonding of the HS
prefers certain conformations above other ones, rotation of the acyl carbonyls from both
sides of the phenyl ring becomes restricted. Temperature increase results in the
disturbance of the H-bonds of the HS in the crystalline phase, which is detected as a
decrease of peaks representing acyl carbonyl in the crystalline form, and an increase of
peaks originating from acyl carbonyl in the amorphous form. Since associated carbonyls
always appear at lower frequencies than their non-associated counterpart22, the peak at
1771 cm-1 has been assigned to H-bonded acyl carbonyl in the amorphous phase (Fig.
7). The fact that this peaks increased with heating, indicated that it can only originate
from the portion of the HS in the amorphous phase participating in the H-bonding with
the amorphous SS. The other observed peak at 1784 cm-1 probably originates from the
non-associated acyl carbonyl of the HS in the amorphous phase (Fig. 7).
The HS crystallinity can be calculated using only peak integral values of the peaks
originating from the urethane carbonyl group at 1680 cm-1 (Fig. 7A, cryst. HS, peak
designated as a) and 1718 cm-1 (Fig. 7A, amorph. HS, peak designated as c). However,
since the acyl carbonyl peaks are a part of the HS and participate in the HS H-bonding, it
seemed more accurate to combine the effect of the two carbonyl groups. Therefore, the
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where ∫ stands for integral values of the peaks a, b, f, g and h as designated in Fig. 7A.
The percentage of the SS crystallinity can be calculated as given in the Equation 3.











As expected, higher percentage of HS crystallinity was observed for PAU1000 with
respect to PAU1500 (Table 1).








*Calculated according to Eq. 2.
**Calculated according to Eq. 3.
In general, PAUs were less microphase separated than the PUs based on the same molar
mass of PCL but with the HS comprised of BDI and BDO (HS cryst.(PCL1000-PU) = 73%
and HS cryst.(PCL1600-PU) = 61%)15. In addition to more hydrolysable HS, this lower
degree of microphase separation renders PAUs more susceptible to hydrolysis (Fig. 3).
3.4. Microphase separation and surface properties of PAUs upon degradation (ATR-FTIR)
Since PAU1000 was distinctly more microphase separated compared to the PAU1500, the
morphology and the surface properties of PAU1000 were analyzed in more detail. ATR-
FTIR, being a surface sensitive technique, provided information on the changes at the
PAU1000 interface, which properties determine the protein deposition and the cell
contact in vivo26-28. The change of surface properties upon degradation was followed by
ATR-FTIR with utilization of the similar deconvolution method derived from the
transmission measurements (section 3.3). Due to optical complications, deconvolution of
ATR-FTIR spectra can only be seen as a semi-quantitative technique. However, since we
used this method to compare samples of the same polymer during degradation by
identical manipulation of all the collected spectra, we consider the method to be
acceptably credible. In order to emphasize the contribution of the acyl functionality to
the hydrolysis of the PAUs, we also plotted the percentage HS crystallinity without the
contribution of the acyl carbonyl peaks (denoted e, f and g in Fig. 7A). This percentage












where ∫ stands for integral values of the peaks a and c as designated in Fig. 7A.
Figure 8. Percentage hard (cryst. HS) and soft segment crystallinity (cryst. SS) upon degradation
of PAU1000. (○) Soft segment (SS) crystallinity (calculated according to Eq. 3), (∆) hard segment
crystallinity with the contribution of the acyl carbonyl peak (HS-with Acyl) (calculated according to
Eq. 2), (▲) hard segment crystallinity without contribution of the acyl carbonyl peak (HS-without
Acyl) (calculated according to Eq. 4).
Compared to the HS crystallinity of non-degraded PAU1000 in the bulk (Table 1),
crystallinity of the HS on the surface was lower (Fig. 8) (in the bulk: 57.5 %, on the
surface ~ 30 %), which indicated that the polar, crystalline HS was initially located away
from the surface. Although the overall crystalline SS content was low, it was
predominantly present at the surface (in the bulk, Table 1: 0.4 %, on the surface, Fig. 8:
~ 5 %), which has been found before in other similar segmented polyurethanes5, 29.
With degradation, the crystallinity of both SS and HS increased at the surface. As
already mentioned, hydrolysis can only occur in the amorphous portions of the PAUs. If
the products of degradation would not diffuse out, the crystallinity of both SS and HS
would remain the same. However, we did observe mass loss (Fig. 2), which can solely be
ascribed to the hydrolysis of the amorphous SS and HS and the diffusion of the
degradation products preferentially from the surface. The SS crystallinity at the surface
increased for ~ 30% after 80 days of degradation (Fig. 8), which was far more than
observed in the bulk (Figure 6A). As already mentioned, PAUs degraded partially via
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surface erosion mechanism. Preferential hydrolytic chain scission at the surface probably
induced higher chain mobility at the surface that allowed for SS crystallization. PCL
crystallization upon degradation was also observed by Lam et al.2 and Antheunis et al.20
Similar to the case of the SS crystallinity increase of PAU1000, the higher chain mobility
at the surface of PAU1000 might have allowed for better HS alignment also, resulting in
higher HS crystallinity at the surface relative to the bulk. Therefore, the increased
crystallinity of both SS and HS upon degradation was most probably the result of both
effects: removal of the degradation products (mass loss) formed by ester and urethane
bond hydrolysis in the amorphous portion of the PAUs, and the effect of the re-
crystallization due to the higher mobility at the surface. The increased hydrogen-bonding
capable hard HS content is expected to render the surface more hydrophilic, which
further enhances cell adhesion30, 31.
The increase in overall crystallinity at the surface of PAU1000 upon in vitro degradation
and surface erosion were expected to result in the increased surface roughness. An
increase of surface roughness can be detected as the contact angle increase. However,
hydrolysis created polar functional groups (carboxyl, hydroxyl or amide) and increased
HS content at the surface of the degraded PAU1000, both contributing to an increased
hydrophylicity, which was observed by a decrease of the contact angle (Fig. 9).
Figure 9. Contact angle of PAU1000 during in vitro degradation; n=5; data expressed as mean ±
standard error of the mean.
Somewhat lower contact angle values for non-incubated sample most probably originate
from the different sample treatment in comparison to the rest of the data collected in the
course of degradation (Fig. 9). After 50-60 days of degradation, the contact angle of
PAU1000 was ~ 65°, which was close to optimal hydrophilicity conditions for cell
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adhesion and proliferation30, 31. It is not possible to speculate what effect would increase
in hydrophobicity (from day 70) cause in contact with cells. However, incubation of
PAU1000 in serum proteins yielded a decrease of contact angle to 60° in only 18 h, most
probably due to an interaction of hydrolytically formed functional groups and amorphous
HS moieties at the surface of PAU1000 (data will be published elsewhere). Upon
implantation, PAU1000 performance is expected to be a result of a complex interplay
between the material surface properties, protein deposition and a type of cells involved.
4. Conclusions
Polyacylurethanes (PAUs) degrade in vitro via combined bulk and surface erosion
mechanisms. Due to a faster hydrolysable hard segment based on terephthaloyl
diisocyanate and lower degree of microphase separation, PAUs degraded much faster in
vitro than comparable PUs with the same polyester (PCL) soft segment. Predominant
chain scission at the surface led to different surface properties of PAUs with respect to
the bulk. Surface erosion and increased chain mobility at the surface resulted in the
increase of both soft and hard segment crystallinity upon degradation. Generation of the
polar groups upon hydrolysis and the increase of the HS content on the surface probably
led to the increase in hydrophilicity, which further renders PAU1000 potentially cell
adhesive. In summary, PAU1000 (molar mass of the oligocaprolactone soft segment =
1000 g/mol) can be recommended as a potential scaffold material to be used in
regenerative medicine due to its optimal in vitro behavior.
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Polyacylurethanes (PAUs) represent a novel class of polyurethanes that can be easily
obtained by reactive extrusion without a use of toxic catalysts. In the case of
polyacylurethane with the number average molar mass (Mn) of the poly(ε-caprolactone) 
oligodiol soft segment of 1000 g/mol (PAU1000), the microphase separated morphology
provided this polymer with mechano-physical characteristics that would render it a
suitable material for constructs and devices i.e. both flexible and strong. The aim of this
study was to assess suitability of PAUs as a temporary scaffold for soft tissue repair.
PAU1000 exhibited excellent haemocompatibility in vitro. In addition, PAU1000 supported
both adhesion and proliferation of vascular endothelial cells and this could be further
enhanced by pre-coating of PAU1000 with fibronectin (Fn). The contact angle of
PAU1000 decreased in biological fluids. In endothelial cell culture medium the contact
angle reached 60°, which is optimal for cell adhesion. Taken together, these results
support the application of PAU1000 in the field of soft tissue repair as a temporary
degradable scaffold.
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1. Introduction
As a result of the present and growing demand for facilitating and enhancing the quality
of human life, regenerative medicine is a rapidly expanding field of research. This trend
is imposing increasing requirements on existing and novel biomedical materials.
Designing biomaterials, biodegradable or inert, that will meet properties of the native
tissue whilst being biocompatible is a major challenge. Although damaged soft tissues
(cardio-vascular, skin, defect closures etc.) engage in intrinsic regeneration and repair
mechanisms, support by a biodegradable scaffold is warranted1, 2. At experimental level,
tissue engineering and regenerative medicine approaches have shown clinical benefit
especially in combination with stem cell technology3, 4 However, the biodegradable
materials currently investigated do not provide all the necessary characteristics because
either they do not meet all the biocompatibility requirements, or they do not support cell
adhesion exhibiting suboptimal degradation behavior with respect to the specific
application.
Novel segmented polyester urethanes (SPEUs) based on terephthaloyl diisocyanate
(TPHDI) have been recently developed in our laboratory5. The results of the in vitro
degradation study of PAUs with different length of the oligocaprolactone soft segment
have been presented in the Chapter 2 of this thesis. PAU characterization included
monitoring mass loss, molecular weight change, and thermal and surface properties
change of PAUs upon a degradation period of 80 days (Chapter 2). PAU1000 (molar
mass of the oligocaprolactone soft segment = 1000 g/mol) was selected as the potential
scaffold material to be used in regenerative medicine due to its optimal behavior during
hydrolytic degradation and suitable micro-phase separation behavior.
Our aim was to develop a degradable and biocompatible polymer with surface properties
that support cell adhesion for use as a temporary scaffold material to support soft tissue
repair.
In this chapter, we evaluated the cytotoxicity and haemocompatibility of PAU1000.
Haemocompatibility experiments included in vitro assessment of thrombogenicity and the
activation of the complement system. In addition, by a series of in vitro assays we
explored a possibility of applying this material in regenerative medicine as a
biodegradable scaffold. Human umbilical vein derived endothelial cells (HUVEC) were
used for in vitro cell adhesion and proliferation experiments.
Since both cell adhesion and blood interactions with biomaterials take place in the





Polyacylurethanes used in this study have been synthesized as described in the Chapter
2 of this thesis.
Polyacylurethane films were cast from chloroform onto PFA Petri dishes (perfluoroalkoxy
polymer resin) obtained from Bergof (Florida, USA) or onto Thermanox® cover slips
which were purchased from NUNC™ (Roskilde, Denmark).
Glutaraldehyde was purchased from Sigma-Aldrich (Zwijndrecht, The Netherlands). RPMI
medium and fetal calf serum (FCS) were obtained from Cambrex Bio Science (Verviers,
Belgium). CellTiter 96® Aqueous One Solution A was purchased from Promega
Corporation (Madison, WI, USA). Polyurethane Pellethane® was a gift from Dow
Chemicals (Midland, MI, USA).
The following materials were used in the haemocompatibility study: Polydimethylsiloxane
(PDMS) from Eriks (Alkmaar, The Netherlands), low-density polyethylene (LDPE)
ET311350 from Goodfellow (Cambridge, UK), thrombin chromogenic substrate S2238 and
chromogenic substrate S2527 from Chromogenix (Milano, Italy).
In cell adhesion and proliferation tests the following materials have been employed:
diamidino-2-phenylindol-dihydrochlorid (DAPI) from Sigma-Aldrich (Germany), Triton X-
100 from Sigma (St. Louis, USA), polyclonal antibody rabbit-anti Ki-67 from Nova Castra
Laboratory (Newcastle, UK), Tween 20 from Sigma-Aldrich (Zwindrecht, The
Netherlands), Avidin/Biotin blocking kit from Vector Laboratories Inc. (CA, USA),
streptavidin-FITC from DAKO (The Netherlands) and Citifluor API from Agar Scientific
(Essex, UK).
2.2 Preparation of polymer films
Polymer films were prepared by casting a 2 w/v % polyurethane solution in chloroform
onto either ID 8 cm PFA Petri dishes or Thermanox® cover slips (treated side up) at
room temperature. Both the freestanding films and the coated slips were washed in a
Soxhlet apparatus utilizing n-hexane as the extraction solvent for 16 h in order to
remove any surface contaminants such as potentially present silicones. Finally, the
materials were dried and stored in the vacuum stove at 40°C until further use.
In some of the experiments, PAU-coated Thermanox® cover slips were additionally
coated with fibronectin (Fn). In brief, 250 μl 1 weight% solution of recombinant human 
Fn in PBS was placed in wells (24-wells culture plate) containing PAU-coated slips and
incubated at 37°C for 30 min. The excess of Fn-solution was aspirated and the adhered
fibronectin was cross-linked with 0.5 % glutaraldehyde (GA) solution in PBS at room
temperature for 15 min. In order to remove all the GA remains, all the coated samples
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were extensively washed with PBS and endothelial cell culture medium (ECM medium)
formulated in our laboratory. The endothelial culture medium (ECM) consisted of RPMI
1640 supplemented with 20% heat-inactivated FSC, 2 mM L-glutamine, 5 U/ml heparin,
100 IE/ml penicillin and 100 μg/ml endothelial growth factor supplement extracted from 
bovine brain.
2.3 MTS cytotoxicity assay
To perform cytotoxicity assays, a fibroblast cell line PK84 was cultured in RPMI medium
containing 10% FCS. Cells seeded in a density of 5,000 cells/well were exposed to an
extract of PAU1000, obtained by shaking the material overnight in culture medium at
37°C. After 48 hours 20 μl of CellTiter 96® Aqueous One Solution A was added to each
well and the absorbance intensity was recorded at 490 nm after 90 minutes of culture.
Pellethane® and latex were used as negative and positive control, respectively.
2.4 Haemocompatibility of PAU
Two different methods were employed to assess the blood compatibility of PAU1000:
Thrombin generation assay and Complement convertase activity. Another biomedical
polyurethane developed in our laboratory by Heijkants et al8 (1,4-butanediisocyanate-
based (BDI) hard segment and PCL-based soft segment) with the same PCL length as
PAU1000, and commonly used reference materials were included in the experiments.
2.5 Thrombin generation assay
The formation of thrombin in the presence of the biomaterial was determined by means
of the Thrombin Generation Assay (TGA) as developed by Haemoscan (Groningen, The
Netherlands). Polydimethylsiloxane (PDMS) and low-density polyethylene (LDPE) were
used as positive and negative control, respectively. Thrombin generation was obtained in
citrate plasma depleted of fibrinogen. Materials (surface area 0.5 cm2) were incubated in
duplicate in 350 μl plasma in polyethylene tubes for 15 min at 37°C. Then CaCl2 (30mM)
and phospholipids were added, gently mixed and after 1, 2, 4 and 6 min, 10 μl of the 
incubation mixture was diluted in 490 μl ice cold 25 mM Tris-HCl buffer to stop further 
thrombin formation or inhibition. These diluted samples were incubated at 37C with 3
mM thrombin chromogenic substrate S2238 for 20 min. The optical density of the yellow
colour was measured at 405 nm in a micro titer plate reader from Powerwave 200 Bio-
Tech Instruments (Winooski, Vermont). A calibration curve was made with known
concentrations of thrombin in Tris buffer.
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2.6 Complement convertase activity
Surface-bound C5 convertase was determined on 1 cm2 material after incubation in
porcine plasma for 15 min at room temperature (CCA, Haemoscan, Groningen, The
Netherlands). After incubation, the samples were rinsed and incubated in chromogenic
substrate S2527) diluted in TRIS buffer at room temperature in the dark for 24 hours.
Thereafter, the optical density was determined at 405 nm in a microplate reader.
2.7 HUVEC adhesion and viability on PAU1000
Human umbilical vein endothelial cells (HUVEC) were isolated and cultured as previously
described 9. In short, the cells were cultured on endothelial culture medium (ECM; see
section Preparation of polymer films) and 1% gelatin coating at 37°C and 5 % CO2.
Polyurethane (PAU1000)-coated Thermanox® cover slips and additionally fibronectin
(Fn)-coated cover slips were placed in 24-well plates and HUVEC (130.000/cm2) were
seeded in each well. After 18 h culture, adhered cells were fixed in 2 %
paraformaldehyde (PFA) in PBS at room temperature for 20 min. Cells were stained with
DAPI in PBS for 30 min. The cell number was determined by fluorescence microscopy
utilizing Leica DC 300F apparatus (Wetzlar, Germany). For the viability test, HUVEC
(150.000/cm2) in ECM were seeded onto either PAU1000-coated cover slips, or Fn-
coated PAU1000 cover slips, and cultured for 4 and 8 h. The adhered cells were
detached with trypsin and the viability was assessed using Trypan blue staining.
2.8 HUVEC proliferation on PAU1000
The HUVEC proliferation was evaluated upon culture on PAU1000, Fn-coated PAU1000,
bare Thermanox® cover slips and Fn-coated Thermanox® cover slips for 25 h. After
culture, the non-adhered cells were removed by washing and the attached cells were
fixed with 2 % PFA in PBS and stored dry at 4°C. For the staining, samples were thawed,
dried and additionally fixed with 2 % PFA in PBS. Fixed cells were permeabilized with 0.5
% Triton X-100 in PBS. Samples were then incubated with polyclonal antibody rabbit-anti
Ki-67 (1:500) at room temperature for 90 min. Subsequently, cells were washed with
0.05 % Tween 20 in PBS. Endogenous avidin and biotin were blocked with Avidin/Biotin
blocking kit for 15 min each. Samples were then incubated with the secondary antibody
goat anti rabbit biotin in DAPI/PBS solution at room temperature in the dark for 30 min.
Thereafter, cover slips were incubated with streptavidin-FITC in DAPI/PBS at room
temperature in the dark for 30 min. All incubation steps were followed by appropriate
washing steps. The cover slips were transferred and fixed onto glass slides, and
mounted in Citifluor API. The cover slips were examined by immunofluorescence
microscopy using a Leica DMRXA microscope and Leica Software of Leica Microsystems
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(Wetzlar, Germany). At least six images were recorded per cover slip and the attached
cells were counted.
Due to the high auto fluorescence of uncoated PAU1000, we also detached the cells after
overnight culture and cytospotted the cells on glass slides for 5 min and speed of 500
rpm using Shendon, Cytospin 3 apparatus. The staining procedure for Ki67 was the same
as previously mentioned.
2.9 Surface characterization of PAU1000
Surface properties of PAU1000 were assessed upon short-term exposure to biological
fluids. PAU1000-coated Thermanox® cover slips were placed in the wells of a 24-well
culture plate and incubated in PBS, ECM supplemented with 20% FCS and 100% FCS at
37°C for 1 h, and 18 h. In both cases, after incubation the samples were rinsed by
means of spraying distilled water against both sides of the samples. The samples were
blotted with tissue paper, free-standing film or cover slips were fixed to glass slides by
double-sided adhesive tape and contact angle was measured using a sessile drop
method using a Krüss Drop Shape Analysis System DSA 10.
2.10 Statistical analysis
A statistical analysis was performed by two-way ANOVA followed by Bonferroni post hoc
analysis using GraphPad Prism software v4 (San Diego, California, USA). Values of p <
0.05 were considered statistically significant.
3. Results and discussion
3.1 Cytotoxicity (MTS assay)
In this study, we performed a reliable and robust method of determining cytotoxicity of
the novel polyacylurethane PAU1000. Mitochondrial activity of PK-84 cells cultured in the
medium containing extracts from PAU1000 was similar to both positive control and the




Table 1. Cytotoxicity determination. Cytotoxicity of PAU1000 was comparable to clinical grade
polyurethane Pellethane®. Controls were Latex (cytotoxic) and medium (non-toxic) (n=4, data
expressed as average±SD).





3.2 Thrombin generation assay
The speed of thrombin generation by PAU1000 was similar to low density polyethylene,
which is lowly thrombogenic, and much lower than polydimethylsiloxane, which served
as i.e. thrombogenic control material (Fig. 4A). The other PCL-based PU, PU1000, was
the least thrombogenic of all the materials tested. Since both the clotting cascade and
platelet phospholipids are involved in this test, the results are clinically relevant. The
good haemocompatibility renders PAU1000 a promising candidate for cardiovascular
applications, e.g. bioartificial vascular grafts.
3.3 Complement convertase activity
Complement convertases are formed by incubating biological fluids, blood or blood
products with biomaterials, allowing the activation of the complement system and
binding of complement convertases to the biomaterial surface. Surface activity of the C5
convertase indicates generation of C5a fragments, which are strong anaphylactic and
chemotactic components and initiation of C5b-9, the terminal complement complex with
cytotoxic capacity. Activation of the complement cascade in the presence of PAU1000
was measured through the activity of complement C5 convertase on the material
surface. In this respect, PAU1000 only minimally activated complement compared to the
other control biomedical materials (Fig. 4B). Both PUs induced very low complement
convertase activity. Therefore, the low C5 convertase activity recorded in the experiment
with PAU1000 would predict to induce only a minimal inflammatory reaction in vivo.
Taken together, the results of these three bioactivity assays (cytotoxicity,
thrombogenicity and complement convertase activity) show that in vitro PAU1000 is
highly biocompatible and warrant for assessment in animal implantation models.
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Figure 4. Haemocompatibility assessment. (A) Thrombin generation assay, (B) C5 complement
convertase activity. Control materials used for comparison: 1,4-butanediisocyanate based
polyurethane (PU1000), polydimethylsiloxane (PDMS) and low density polyethylene (LDPE) as the
Gold standard (mean values of duplicate measurements ± SD).
3.4 HUVEC adhesion to PAU1000
Adhesion of human umbilical vein endothelial cells (HUVEC) to PAU1000 was monitored
for 18 h. Based on the hydrophobic nature of PAU1000, we expected only a low
adhesion of HUVEC to the PU. However, the difference in contact angle values between
PAU1000 (78.0°±2.6°) and Thermanox® cell culture treated cover slips (71.1°±1.6°)
was similar. Thus, in this setting hydrophobicity was not the only parameter governing
the cell adhesion. We assume that the presence of carboxyl functionality on the surface
of Thermanox® cover slips renders the surface more cell-adhesive. In order to further
enhance cell adhesion, we included samples that were additionally coated with
fibronectin. Fibronectin possesses integrin binding motifs such as the RGD (Arg-Gly-Asp)
sequence that could augment the attachment of HUVEC10, 11. Initially, the number of
adhered cells increased regularly with time, irrespectively of Fn-coating, with Fn-coated
PAU1000 cover slips providing faster cell adhesion for the period up to 4 h (Fig. 5A).
HUVEC cultured on PAU1000 exhibited a steady increase in the number of adhered cells,
resulting in a similar degree of adhered HUVEC on both Fn-coated and bare PAU1000. In
order to elucidate the observed phenomenon of decrease of cell adhesion between the
points 4h and 8h, the viability was measured using Trypan blue dye exclusion. The
number of viable cells that adhered after incubation was at both time points more than
80 % (Fig. 5B), which was similar to the other time points (data not shown). Although
the cells remained viable throughout the test period, some had detached from the Fn-
coated slips after 8 h of culture. Since Fn is hydrophobic, a property that does not
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depend on the nature of the underlying substrate12, the hydrophobic interaction of Fn
with PAU1000 is strong. These strong hydrophobic interactions could have caused
adverse conformational changes in the Fn molecules that impaired cell adhesion.
Furthermore, Fn-coating might have partially lost during prolonged culturing, thus
exposing the cells to the less adhesive bare surface of the PAU1000. In the later stages
of incubation, adhering HUVEC started producing their own adhesive extracellular matrix
molecules such as collagen and fibronectin (data not shown)13. This cellular activity
might be the reason why with prolonged culture time (overnight), the difference
between the HUVEC adhesion to bare PAU1000 and Fn-coated PAU1000 was diminished
(Fig. 5A). A possible explanation for low cell adhesion to PUs could be that the PU
surface exposed to plasma proteins is mostly covered with proteins that are generally
considered non-adhesive. Fibrinogen is initially adhered, but it is competed for deposition
on the polyurethane surface with albumin, high-density lipoprotein and high molecular
weight kininogens (HMWK), which all do not favor cell binding14. The dynamics of the
rearrangement and replacement of proteins on the PU surface is determined by the
hydrophobicity and the degree of polyurethane micro-phase separation13, 15-17. This
influences protein mobility and rearrangement for better recognition by cell integrins13.
Proteins interact with the polyurethanes via hydrophobic interactions (soft segment
domains) and/or hydrogen bonding (hard segment). Highly hydrophobic substrates bind
more protein as compared to more hydrophilic substrates. The hard segments are
reported to bind fibrinogen via hydrogen bonds16. Being more adhesive, the hard
segment is also known to interact with platelets and lead to their activation17, 18. To
contribute to the complexity of polyurethane-protein and cell interaction, a polyurethane
surface is also dynamic and might rearrange to promote better adhesive properties by
exposure of hard segments. A dry PU surface, being in contact with air, which is
hydrophobic, has soft segments mostly exposed19. Upon immersion in water, more polar
hard segments capable of hydrogen bonding migrate to the surface, making it more
hydrophilic. The decrease in contact angle observed for PAU1000 upon contact with
biological fluids (Fig. 6).
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Figure 5. Adhesion and proliferation of endothelial cells (HUVEC) on PAU1000.
(A) HUVEC adhesion to PAU1000 (■) and Fn-coated PAU1000 (▲) monitored up to 18 h. (n=3; 6
images per cover slip, data expressed as mean ± standard error of the mean; asterisks indicate
significant differences *p < 0.05). (B) Viability test of HUVEC during adhesion to PAU1000 and Fn-
coated PAU1000 (PAU1000+Fn) at 4 and 8 h (n = 2; 6 images per cover slip, data expressed as
mean ± standard error of mean; asterisks indicates significant difference *p < 0.05 ). (C) HUVEC
proliferation after 25 h culture on PAU1000, Fn-coated PAU1000, Thermanox® cover slips (Therm)
and Fn-coated Thermanox® cover slips (Therm+Fn) (n = 2; 5 images per cover slip, data
expressed as mean ± standard error of the mean).
3.5 HUVEC proliferation on PAU1000
Even though the rate of HUVEC adhesion may appear low, longer incubation
experiments of 25 h revealed that both bare PAU1000 and Fn-coated PAU1000 allowed
for significant HUVEC proliferation, reaching almost 50% cellular confluence already after
25 h of culture, which was similar to the Thermanox® cover slips (Fig. 5C). That
indicates that fast and efficient in vitro endothelialization of grafts fabricated from
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PAU1000 is feasible. The additional coating with Fn appeared to further increase the
number of proliferating cells on PAU1000, although it had little influence on Thermanox®
cover slips.
Figure 6. Contact angle of PAU1000 exposed to biological fluids: phosphate buffer saline
(PAU1000 in PBS), endothelial cell culture medium (PAU1000 in ECM) and fetal calf serum
(PAU1000 in FCS). References included: non-incubated PAU1000 (Non-incub. PAU1000) and non-
incubated Thermanox® (Non-incub. Therm). All the values, except where indicated (n.s.) were
statistically significantly different (n=5; data expressed as mean ± standard error of the mean).
3.6 Surface characterization
To model the biological environment of the potential PAU implant in vivo, the changes of
the surface properties of PAU1000 in contact with biological fluids was investigated.
Coated on the Thermanox® cover slip, the contact angle of the PAU1000 in a dry state
was 78.0°±2.6° while the one of Thermanox® cover slips was 71.1°±1.6° (Fig. 6). After
incubation in PBS at 37°C for 1 h, and 18 h the contact angle had slightly decreased, but
after the incubation in ECM and FCS a noticeable increase of surface hydrophylicity,
compared to the non-incubated sample, was observed, with the contact angle of
PAU1000 incubated in FCS reaching 45.0o±7.2° (Fig. 6). This increase of PAU1000
hydrophylicity could explain the best HUVEC adhesion result at longer culture time. After
18 hours incubation in ECM, the PAU1000 surface contact angle was 60°, according to
literature an optimal value for the best cell adhesion20. Most probably surface
hydrophobicity changed due to an increase in hard segment content on the PAU1000
surface as a result of the interaction of hard segment with water and proteins at the
interface in combination with products of the surface erosion process.
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4. Conclusions
Polyacylurethanes are hydrolytically degradable materials that can be easily obtained by
reactive extrusion without a use of any potentially toxic catalysts. A combination of bulk
degradation and surface erosion might be responsible for peculiar degradation behavior
of this polymer. In vitro, PAU1000 behaved as a non-toxic and blood compatible
biomaterial. In addition, PAU1000 supported adhesion and proliferation of human
umbilical vein endothelial cells. Taken together, these results support the application of
PAU1000 in the field of soft tissue repair as a temporary degradable scaffold.
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The aim of this study was to design biomedical polyurethanes (PUs) that would
hydrolyze faster than poly(ε-caprolactone) (PCL) based PUs. A series of γ-butyrolactone 
(γ-BL) and ε-caprolactone (-CL) co-polyesters with molar weights (MW) between 700 -
2150 g/mol was prepared by 1,4-butanediol initiated ring-opening polymerization (ROP),
catalyzed by Candida Antarctica Lipase B (CAL-B; Novozyme 435) at room temperature.
A maximum of 26 mol% of γ-BL could be incorporated in the oligodiols with relatively 
good product yield. Introduction of hydrophilic γ-BL disturbed PCL crystallization and 
resulted in enhanced hydrolytic degradability of PBCL-PUs. The oligodiols were
successfully converted into the PUs by the end-capping with 1,4-butanediisocyanate
(BDI) and subsequent chain-extension with 1,4-butanediol (BDO). The thermal and
mechanical properties of the PUs are shown to depend on the oligodiol MW. With the
increase in oligodiol MW, the PU crystallinity and the degree of the microphase
separation decreased, followed by a decrease in the Young’s Modulus. The proposed
manufacturing route to obtain oligodiols for the synthesis of biomedical PUs is attractive
due to the employment of the low-cost monomers (γ-BL and ε-CL), efficient and easily 
removable catalyst and low reaction temperature. Furthermore, PBCL-PUs were shown to
be biocompatible both in vitro and in vivo, which renders this type of PUs excellent
candidates for manufacturing of scaffolds to be used in tissue regeneration.
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1. Introduction
A tremendous amount of research has been devoted to the applications of degradable
polymers for biomedical devices. Especially the potential of degradable scaffolds for
temporary support in tissue regeneration has drawn a lot of attention in scientific
research1-4. Currently the first applications appear in the clinic5, 6. Traditionally, aliphatic
polyesters were considered materials of choice for design of scaffolds for medical
applications. However, they suffer from poor mechanical properties, as they have low
glass transition temperature (Tg) and mechanical stability can only be achieved by
allowing the polyester to crystallize at least partially. The presence of crystals impairs
degradability and was seen to cause inflammation upon implantation, such as in case of
the resorbtion of polylactic acid bone fixation plates7, 8.
Aliphatic, segmented, thermoplastic polyester urethanes represent a superior class of
polymers where properties are easily adapted to the desired requirements. A key feature
of segmented polyester urethanes (SPEUs) is the phenomenon of microphase separation
in the material between the urethane segments and the polyester segments leading to
the physical crosslinking of the molecules, thereby providing the superior mechanical
properties of the polymeric materials9-12. This phenomenon is determined by the
thermodynamic incompatibility between the urethane and polyester segments and
depends on the chemical constitution and chain length of the blocks9, 11. In SPEUs
therefore the microphase separation depends on the type of polyester and urethane and
their molar weight and molar weight distribution.
In vitro, SPEUs mainly degrade by bulk hydrolysis of the ester and urethane groups by
absorbed water. This can be ascribed to the low value of the equilibrium constant for the
ester formation while urethane groups were shown to be far less sensitive for hydrolytic
scission13-15. Degradation results in water soluble and metabolically consumable, i.e.
resorbable degradation products. The degradation rate is therefore dependent on the
rate of random chain scission, and diffusability and solubility of the transient degradation
products (short oligoesters and monomers)16, 17.
1,4-Butane diisocyanate(BDI)-based SPEUs have been extensively studied in our
laboratory18-20. Heijkants et al. designed poly(ε-caprolactone)-BDI-based segmented PUs
for meniscus regeneration20. The PUs were shown to be biocompatible in vivo21.
However, these PCL-PUs were found to degrade very slowly and were still present in the
test animals two years after implantation22. However, due to the relative high
hydrophobicity of the monomer23, degradation is rather slow and biomedical applications
therefore include only those devices and scaffolds where prolonged survival of the
material is required. For those tissues which regenerate faster this prolonged presence of
the scaffold might become an obstacle for full tissue regeneration. Therefore, SPUEs with
tunable degradation profiles are needed for further extending the application area of this
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remarkable class of biomedical materials. The degradability of these PUs can be
enhanced by the incorporation of other more hydrophilic co-monomers in the synthesis
of oligodiols.
Poly(4-hydroxybutyrate), a polyester produced microbially, was successfully applied in
the tissue engineering of small caliber vascular grafts24 and trileaflet heart valves25,
providing a good substrate for cell attachment and proliferation. However, with or
without the help of a catalyst, the monomer γ-butyrolactone (γ-BL) was initially found to
be chemically non-polymerizable26. The low reactivity of γ-BL has been ascribed to the
low ring strain27, 28. The attempts that followed were mainly focused on the design of
novel catalysts and initiators such as organometallics29-31, lanthanides32, 33 or
molybdenum34 compounds. In all cases γ-BL homopolymerization yielded very low molar
weight products (MW) in low yield29, 35. However, the copolymerization of γ-BL with the
other lactones was more successful. Even though some chemical pathways delivered
relatively high MW γ-BL-containing polyesters29, 33, 36, the biocompatibility of the applied
catalysts represents a highly important issue. Although a catalyst per se is not toxic, it is
almost impossible to fully predict its fate and an effect they could provoke in vivo. The
hydrolysability and the (bio)degradation of the copolyesters were observed to increase
with the incorporation of the γ-BL units36-38, which made the γ-BL-containing polyesters
interesting candidates for biomedical applications.
The discovery of enzymes as catalysts that could be employed in the ring-opening
polymerization (ROP) of lactones39-43 (among vast majority of other reactions) broadened
the range of possibilities for obtaining γ-BL copolyesters44, 45. Enzymes are especially
attractive for manufacturing of biomaterials since they remain solid during the
polymerization and could be as such easily removed from the reaction mixture, rendering
the biomaterials free of potentially toxic catalysts.
The aim of this study was to develop novel biodegradable PUs with enhanced
degradability as potential biomaterials for scaffold preparation. By varying reaction
parameters, we prepared a series of oligodiols based on ε-CL and γ-BL utilizing an
immobilized lipase, Candida Antarctica (CAL-B; Novozyme 435). The oligodiols were
further successfully reacted with the BDI and subsequently chain-extended with 1,4-
butanediol (BDO) to yield the PU. In vitro degradability of the novel PUs was assessed
and compared to similar poly(ε -caprolactone)-BDI-based PUs.
2. Material and Methods
2.1 Materials
γ-Butyrolactone (γ-BL), 1,4-butanediol (BDO) and toluene, all analytical grade reagents
were purchased from Aldrich (Zwijndrecht, The Netherlands). BDO was distilled from 3Å
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mol. sieves. Toluene was freshly distilled over sodium. ε-Caprolactone (ε-CL) was
obtained from Union Carbide (Terneuzen, The Netherlands) and was purified by
distillation under reduced pressure from calcium hydride (CaH2). 1,4-Butanediisocyanate
(BDI) was purchased from Bayer (Leverkusen, Germany) and it was subsequently
distilled under reduced pressure by means of a short-path distillation. Novozyme 435
was a kind gift from Novozymes (Luud, Sweden). Novozyme 435 was stored dry in a
refrigerator at 4°C. Chloroform and n-hexane as analytical grade solvents were
purchased from Acros (Geel, Belgium) and were used without further purification.
2.2 Synthesis of γ-BL/-CL oligodiols
The reactions between γ-BL and ε-CL monomers (molar ratio γ-BL and ε-CL varied:
0/100, 20/80, 40/60, 50/50 and 100/0), and initiator (BDO) (molar ratio ε-CL/BDO
varied: 4.5/1, 10/1, 12/1, 15/1 and 20/1) with Novozyme 435 (typically 1 g per 11 g of
reaction mixture) as a catalyst were conducted in freshly distilled toluene for 22 h on the
shaking platform at ambient temperature. All the reactions were performed in thoroughly
cleaned and dried glassware under argon gas. After the polymerization, the resulting
reaction mixture was diluted by adding ~ 10 mL of chloroform to the reaction flask.
Novozyme 435 was filtered out through a P4 glass filter and 0.1 μm syringe PTFE filter 
(PURADISC, Whatman). The collected filtrate was subjected to reduced pressure at a
Rotavap apparatus in order to remove chloroform and toluene. Unreacted monomers
and remaining solvents were removed by short-path distillation (Büchi GKR-51,
Switzerland) with gradual temperature increase from ambient temperature to 80°C at
the pressure of ~ 0.02 mbar.
2.3 Synthesis of PUs
Polyurethanes were prepared via a two-step procedure according to the method
developed by Heijkants et al.20. Briefly, in the first step oligodiol obtained as previously
described was end-capped with the 6-fold excess of BDI and reacted for 3.5 h with
magnetic stirring at 80°C. Prior to the second step, the excess of the diisocyanate was
removed by short-path distillation at 80°C until constant mass was reached.
Subsequently, the end-capped oligodiol was chain-extended with a slight excess of BDO
(1:1 to 1.2:1) for 16 h at 80°C. The use of catalyst was avoided in both reaction steps.
The obtained PU (denoted PBCL-PUs in further text) was released by breaking the glass
flask and stored at 4°C until further use.
2.4 1H-Nuclear magnetic resonance (1H-NMR)
The sample preparation consisted of dissolving approximately 15 mg of either oligodiol
or PBCL-PU in ~ 0.8 mL of deuterated chloroform (d-chloroform).1H-NMR spectra were
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recorded at room temperature using a 300 MHz Varian NMR apparatus. 1H-NMR was
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2.5 Gel permeation chromatography (GPC)
MWs and polydisperisities of oligodiols were determined by a GPC system consisting of a
Spectra Physics P1000 pump, Spectra Physics AS 1000 auto-sample injector, Viskotek H-
502, Shodex RI-71 detector and a set of two PL gel mixed C columns maintained at
30°C. THF was used as an eluent with the flow rate of 1.0 mL/min. The injected volume
was 100 μL (concentration 3 mg/mL). All samples were filtrated over a 0.45 μm filter 
prior to measurement. Universal calibration with polystyrene (PS) standards was
performed. Data analysis was conducted with the Trisec GPC version 3.0 software
package.
MWs and molar weight distribution (D) of the PBCL-PUs were determined by utilizing
DMF with 0.01 M LiBr as an eluent on a Waters 600 Powerline system, equipped with 2
mixed-C PL gel 5 μm columns (Polymer Laboratories) at 70°C. All samples were filtrated 
over a 0.45 μm filter prior to measurement. The data analysis was done using 
conventional calibration with PS standards accompanied by in-house software.
2.6 Attenuated Total Reflectance Fourier-Transform Infrared spectroscopy (ATR-FTIR)
Infrared spectroscopy was performed using a Bruker IFS88 equipped with a Golden Gate
(Graseby Specac) single reflection ATR accessory, with the spectral resolution of 4 cm-1.
Fifty scans were taken to obtain each spectrum. OPUS version 4.2 software was used to
analyze the data.
2.7 Differential scanning calorimetry (DSC)
Thermal analysis of oligodiols and the PBCL-PUs was assessed by means of DSC (Perkin-
Elmer DSC-7). The measurements were performed with the heating rate of 10°C/min
under a nitrogen atmosphere. TA software version 4.0 was employed in the analysis of
the resulting endotherms.
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2.8 Tensile test
For the tensile test, PBCL-PU films were cast from 1,4-dioxane solution (concentration 2-
3 wt%) onto PFA Petri dishes (perfluoroalkoxy polymer resin; Bergof, Florida, USA) at
room temperature for at least 48 h. The films were finally dried in vacuum at 40°C for at
least 16 h. Tensile tests were performed on rectangular-shaped specimens (40 x 2.2 x
0.1 mm) cut from the PU films 21°C with a 100 N load cell, using an Instron 4301 tensile
tester, and an extension rate of 10 mm/min.
2.9 Degradation study
To assess in vitro degradation, one of the PBCL-PUs, PBCL1620-PU (sample: 4 x 4 x 4
mm3; mass: 0.13 0.03 g; n = 1) was subjected to hydrolysis by immersion in phosphate
buffer (solution in water, pH = 7.2; Sigma-Aldrich, Zwijndrecht, The Netherlands)
supplemented with sodium azide (0.02 wt%) protected from light at 37°C for a period up
to 17 weeks. At each analysis point, a sample was withdrawn, blotted, weighed, dried for
24 h at 40°C under vacuum and weighed again. The mass loss and water uptake were
determined according to Eq. 3 and Eq. 4, respectively.
0 d
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  Equation 4
with mo is the mass before incubation, md is the mass after drying and mw is the mass of
the wet sample.
MWs of the degraded PBCL1620-PU were determined by GPC. The measurements were
done on a GPCmax VE-2001 with model 302 TDA detectors and Omnisec software
(Viscotek), using DMF with 0.01M LiBr at 70°C as eluent. The columns (PLGel 5μ 2x30 
cm mixed-C from Polymer Laboratories) were calibrated using universal calibration with
narrow disperse PMMA standards (Polymer Laboratories). Hydrolytic rate constants were
determined by fitting GPC data by linear regression analysis option of the OriginPro 7.5
software.
3. Results and Discussion
3.1 Synthesis of oligodiols and PUs
In this study we demonstrate that we were able to synthesize a set of novel
biodegradable PUs by BDO-initiated, enzyme-catalyzed ROP of ε-CL and γ-BL and
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subsequent reaction of the oligodiols with an aliphatic diisocyanate (BDI), and a chain-
extender (BDO) (Fig. 1).
Figure 1. Enzymatic polymerization of γ-BL with ε-CL and PBCL-PU reaction scheme.
Due to its low ring strain (36.5 KJ/mol as compared to ε-CL ring strain of 44.7 KJ/mol)28,
γ-BL does not polymerize readily via conventional preparative methods. Since the
enzymatic catalysis of the polymerization only requires a recognizable reactive centre
and does not depend on the ring strain of the lactone, several research groups employed
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various lipases for the ROP of γ-BL and other lactones44-46. The enzyme activity and
efficiency in the ROP was proven to be higher if the lipases were immobilized on an inert
carrier47. Therefore, an immobilized enzyme, lipase CAL-B (trade name Novozyme 435)
was chosen as a catalyst. Preliminary experiments at 60°C and 80°C with stirring of the
reaction mixture disrupted the morphology of the Novozyme 435 beads, and could lead
to difficulties of fully removing small catalyst particles from the reaction mixture. In
addition, when similar experiments were repeated at room temperature with shaking,
oligodiol MWs and yields were comparable to the ones obtained at higher temperatures.
Bearing in mind that the efficacy of enzymes might decrease in organic solvents at
higher temperatures, we chose to conduct the reactions at the milder reaction
conditions.
Table 1. Oligodiols with different feed composition. PCL - ε-CL homopolymer; PBL - γ-BL
homopolymer; PBCLxx - copolymer of γ-BL and ε-CL with xx mole % feed ratio of ε-CL; PBCL-
yyBDO - 50/50 mol% feed ratio of γ-BL and ε-CL with yy ε-CL/BDO mol% ratio. All reactions were















PCL100 0 / 100 4.5 / 1 73 0 / 100 702 1185 1.40
PBCL80 20 / 80 4.5 / 1 68 17 / 83 783 850 1.71
PBCL60 40 / 60 4.5 / 1 65 15 / 85 758 940 1.72
PBCL50 50 / 50 4.5 / 1 43 26 / 74 772 920 1.65
PBCL50(-cat)c 50 / 50 4.5 / 1 0 - - - -
PBL100d 100 / 0 - 0 - - - -
PBL100 100 / 0 - 7 100 / 0 276 410 2.17
PBCL-10BDO 50 / 50 10 / 1 n. m. 24 / 76 1250 1465 2.00
PBCL-12BDO 50 / 50 12 / 1 63 25 / 75 1620 n. m. n. m.
PBCL-15BDO 50 / 50 15 / 1 58 18 / 82 2126 1760 2.25
PBCL-20BDO 50 / 50 20 / 1 54 23 / 77 2134 2200 2.43
a - Determined by 1H-NMR
b - Determined by GPC
c - Reaction conducted without the catalyst
d- Homopolymerization of γ-BL in bulk
n.m. - not measured.
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Table 1 summarizes the results of the synthesis and characterization of a set of γ-BL
copolymers and ε-CL with variable feed ratios of monomers and the initiator (BDO). The
γ-BL homopolymer could not be obtained in the bulk. Conducting the reaction in toluene
delivered a product with an unsatisfactory yield and MW. Similar observations have been
reported by Nobes et al.44. They polymerized γ-BL in the presence of porcine pancreatic
lipase or Psudomonas cepacia at 60°C for almost 8 days only to obtain 900 g/mol
homopolymer. A negative control, the reaction between γ-BL and ε-CL performed
without the employment of the Novozyme 435, did not yield any product, confirming that
the rest of the synthesized oligodiols were indeed enzyme-catalyzed. The polymerization
yield of copolymers was between 43 wt% and 68 wt%, which is comparable to the
maximal 62 wt% yield of copolymers of γ-BL and ε-CL obtained by He et al. also utilizing
Novozyme 435 as the catalyst45. In cases where other, non-immobilized lipases were
used, the copolymer yields were generally lower44, 46.
The chemical compositions, the MWs and the polydispersity of the oligodiols were
determined with 1H-NMR spectroscopy (Fig. 2A) and GPC (Table 1). Experimentally
determined γ-BL/ε-CL ratios revealed that the percentage of build-in γ-BL did not depend
on the initial feed ratio. A maximum of 26 mol% γ-BL was incorporated in the oligodiol.
Similar results have been observed by various research groups. Regardless of the chosen
synthetic pathway, chemo-synthesis30, 34, 36, 48 or enzymatic catalysis45, a maximum of 18
mol% of γ-BL48 incorporation was found. Low incorporation of γ-BL in the chemo-
synthesis of γ-BL copolymers could be explained by already mentioned low reactivity of
the γ-BL ring due to the low ring strain28. The enzymatic catalysis proceeds via a
different mechanism and is not influenced by the lactone ring stability. It is believed that
the enzymatically catalyzed ROP proceeds more readily with hydrophobic substrates49.
Therefore, the lower hydrophobicity of γ-BL compared to the ε-CL, renders the lactone
less prone to the lipase approach.
As expected, decreasing the amount of BDO resulted in the higher MWs of the oligodiols
(Table 1). The obtained oligodiol MWs were in the range of 700 g/mol to 2130 g/mol.
The polydisperisities of oligodiols (D; Table 1) increased with the increase of the oligodiol
MW. The oligodiols were designed to be further used in the synthesis of the PBCL-PU
copolymers similar to the polyester urethanes developed by Heijkants et al50. They
shown that higher oligodiol polydispersity decreases the microphase separation of PUs
and consequently leads to poorer mechanical properties. However, as shown later in this
paper, the microphase separation and the mechanical properties of PBCL-PUs were not
affected.
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Figure 2. Thermal properties of oligodiols. Tm1 - 1st melting temperature; Tm2 - 2nd melting
temperature; ΔHm - enthalpy of melting. The results are extracted from the 2nd heating scan.
A) Dependence of thermal properties of oligodiols in respect to the γ-BL mole content. The graph
represents thermal properties of oligodiols with the MW of 770 g/mol on average.
B) Dependence of thermal properties of oligodiols with respect to the oligodiol MW. The graph
represents thermal properties of oligodiols with the 23 mol% of γ-BL on average.
3.2 Thermal analysis
In addition to chemical composition of γ-BL/ε-CL oligodiols, their thermal properties were
also studied (Fig. 2). The melting temperatures of all the copolymers were lower then
the melting temperature of the PCL homopolymer. Furthermore, the increase in the γ-BL
content (for the same oligodiol MW) led to the decrease of the melt enthalpies (Fig. 2A).
An explanation for this behavior can be related to the disturbance of PCL crystallization
by the insertion of the γ-BL units. This has also been observed by He et al.45 and
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Nakayama et al.36. In all the oligodiols, including the PCL homopolymer (all
enzymatically-catalyzed) a double melting peak was detected (Fig. 2A). A possible cause
for the additional melting peak could be a crystallization of cyclic oligodiols which were
possibly formed51-53. Two different melting peaks indicate a presence of the two different
crystalline structures. However, only one peak was observed in GPC chromatographs
indicating that either that cyclic oligodiol structures were removed by filtration during
GPC sample preparation, or that their concentration was very low, hence, not detectible.
With the variation of the oligodiol MW with similar γ-BL contents, the melting
temperatures and the corresponding enthalpies of melting increased (Fig. 2B). This can
be related to the thermal properties observed for the series of PCL homopolymers of
comparable MWs20.
3.3 ATR-FTIR analysis
Oligodiols were further reacted into PUs. The conversion of oligodiols into PUs was
proven by the ATR-FTIR analysis (Fig. 3A). From the ATR-FTIR measurements (Fig. 3A),
three distinctive vibration bands have been detected in the PUs that were not present in
the oligodiol spectra: at 3300 cm-1, 1680 cm-1 and 1535 cm-1, originating from N-H
stretching vibration, carbonyl stretching vibration (amide I) and NH deformation
vibration (Fig. 3A). As can be seen from the Fig. 3B, the ratio between the ester
(oligodiol) carbonyl stretching vibration (at 1725 cm-1) and the carbonyl amide I changed
with the soft segment (oligodiol) length. It is clear that the amide I peak decreased with
the increase in oligodiol length. The latter is the result of the decrease of the hard
segment content and lower degree of microphase separation.
Figure 3. ATR-FTIR analysis. A) Conversion of oligodiol (PBCL2130) into the PU (PBCL2130-PU).
ν(N-H) at 3319 cm-1, νa(CH2) at 2960 cm-1, νs(CH2) at 2935 cm-1, ν(C=O) ester at 1721 cm-1,
ν(C=O) urethane at 1682 cm-1 (amide I), δ(N-H) and ν(CO-N) (amide II) at 1533 cm-1.
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B) Influence of the oligodiol MW on the ration between ester carbonyl vibration ν(C=O) and the
urethane carbonyl vibration ν(C=O) (amide I).
3.4 Characterization of the PBCL-PUs
The MWs of the PBCL-PUs were in the range of 43,000 g/mol to 65,000 g/mol (Table 2).
The polydispersity increased with the increase in the oligodiol MW, which could be
related to the higher polydispersity of the longer oligodiols (Table 1).
Table 2. Polyurethane characterization. Mn- number average molar weight, Mw - weight average
molar weight, D - polydisperisity; Tg - glass transition temperature, Tm,h - hard segment melting
temperature, ΔHm - enthalpy of melting; HSCTH - hard segment content calculated as in
reference54, CHSCA - crystalline hard segment calculated based on the crystalline hard segment



















PCL700-PU 48200 82400 1.71 - 41.5 131.3 42.7 0.34 64 59
PBCL760-PU 42700 67850 1.59 - 45.4 129.2 43.0 0.33 67 61
PBCL1250-PU 44450 74600 1.68 - 58.1 103.1 23.0 0.24 49 45
PBCL1620-PU 65000 151600 2.33 - 47.2 100.5 22.8 0.19 56 51
PBCL2130-PU 49600 141850 2.86 - 60.9 71.9 6.3 0.14 23 21
As depicted in Fig. 4, an increase of the oligodiol MW resulted in the decrease in the
hard segment melting temperature (Tm,h) and the enthalpy of melting (ΔHm,h).
Based on the measured ΔHm and a value for the melting enthalpy of a theoretically 100
% crystalline hard segment, the crystallinity of the PBCL-PUs was calculated according to
already described method20. From the Table 2, it was clear that the hard segment
crystallinity decreased with the increase of the soft segment portion in the PU. For
instance, only 23 % of the hard segment in PBCL2130-PU was crystalline, indicating that
hardly any microphase separation had taken place. The glass transition temperature (Tg)
of the PBCL-PUs decreased 15°C when the oligodiol molar weight was increased from




Figure 4. Thermal properties of the polyurethanes. Tm,h - hard segment melting temperature; Tg -
glass transition temperature; ΔHm,h - hard segment enthalpy of melting. The results are extracted
from the 2nd heating scan. The graph represents the relation between the thermal properties of
the PBCL-PUs and the oligodiol MW. The graph represents thermal properties of oligodiols with the
23 mol% of γ-BL on average.
Tensile tests showed that with the increase in oligodiol MW, PBCL-PUs turned from
relatively inelastic (brittle) to ductile materials (Fig. 5).
Figure 5. Mechanical properties of PBCL-PUs.
As expected, the increase in the oligodiol MW, i.e. decrease in the hard segment
crystallinity and the degree of microphase separation, the Young’s Modulus decreased.
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The Young’s Modulus of PBCL1620-PU was slightly higher than the Young’s Modulus of
PCL-PU with the same oligodiol MW (85 MPa in comparison to 64.6 MPa)54. Although
PBCL1620 oligodiol polydispersity was higher than the polydispersity of the
corresponding PCL oligodiol, the mechanical properties were not affected.
3.5 Degradation of PBCL-PU
To evaluate if novel PBCL-PUs degrade faster than PCL-PUs, PBCL1620-PU was exposed
to hydrolytic degradation for a period of 17 weeks (119 days). As can be observed from
Fig. 6, approximately 1 wt% mass loss was detected during a course of the degradation
study. Even though this mass loss is not high, Heijkants et al. did not observe any mass
loss when PCL-PUs were incubated for more than a year54. Linear fit of the mass loss
data (Fig. 6) reveal the mass loss rate for PBCL1620-PU of 0.007 wt% per day, which
would lead to mass loss of ~ 4 wt% after 2 years. This percentage is 10 times as high as
mass loss observed when PCL and copolymer of trimethylene carbonate (TMC) and ε-CL
were subjected to in vitro hydrolysis55. The observed mass loss indicated that PBCL1620-
PU degraded at least partially by surface erosion mechanism17.
Water uptake of PBCL1620-PU was almost constant during the course of degradation
with an average value of 0.6 wt%. This finding corresponds well with results of Heijkants
et al.54 for water uptake of non-degraded PCL-PU films of 1.0 wt%. Although this
percentage appears low, it should be taken into account that the corresponding molar
percentage of water is higher. Initial number of ester groups per PBCL1620-PU chain
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where N is number of ester groups per PBCL1620-PU chain of initial Mn of 65,000 g/mol
(Mn0) and Mn (PBCL) is PBCL oligodiol MW (1620 g/mol). Number of moles of ester
groups per PBCL1620-PU chain can be calculated for the initial amount of PBCL1620-PU,
which yields 1.14 x 10-4 moles for a sample of 0.13 g. This finally leads to the molar ratio
of water/(ester groups) of ~ 4/1, which represent considerable amount of water
available to hydrolyze the PBCL1620-PU sample.
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Figure 6. Mass loss and water uptake during hydrolytic degradation of PBCL1620-PU.
As expected for typically bulk degrading polymers, such as higher MW PCL and PCL-PU,
number average and weight average MWs of PBCL1620-PU and the polydispersity
decreased during the course of degradation (Fig. 7). Mn data were further used to
determine the rate of the hydrolytic degradation of PBCL1620-PU.
Figure 7. Number average molar weight and polydispersity of PBCL1620-PU during hydrolytic
degradation.
In vitro degradation of polyester urethanes is primarily ascribed to hydrolysis of the ester
functionality of the oligodiol. If we treat PBCL-PUs as aliphatic polyester, the hydrolysis
rate can be determined assuming two mechanisms: autocatalytic and non-catalytic56, 57.
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Poly(-hydroxyesters) (such as PCL), are known to be bulk eroding polymers57, 58. Due to
the build up of the carboxylic acid formed during hydrolytic degradation, ester hydrolysis
is acid catalyzed59. Pitt et al. derived the following equation to describe the autocatalytic
ester hydrolysis process as a pseudo-first order kinetics57:
0
n nln( M ) ln( M ) k t   Equation 6
where Mn [gmol-1] is number average molar weight of polymer at any time point, Mn0 is
initial number average molar weight [gmol-1], k is hydrolysis rate constant [day-1] of
and t is degradation time [day]. Eq. 6 is based on the following assumptions: 1) extent
of chain scission is small, 2) only ester bonds hydrolyze and 3) there is no mass loss. By
linearly fitting the Mn degradation data of PBCL1620-PU according to the Eq. 6 (Fig. 8), k
value of 3.45 x 10-3 day-1 was obtained, which was two times as high as k of comparable
PU based on PCL oligodiol soft segment of approximately the same Mn54. Although the
hydrolysis rate values for pure PCL polyester determined by different research groups
assuming autocatalytic degradation mechanism differ significantly (Pitt et al.58.: 1.8 x 10-
3 day-1; Pêgo et al.55.: 3.1 x 10-3 day-1, Anthunis et al.60: 0.42 x 10-3 mol-1day-1), we
showed that PBCL1620-PU degrade faster.
Figure 8. Linear fit of PBCL1620-PU Mn measured during in vitro degradation assuming
autocatalytic hydrolysis mechanism (according to Pitt et al.57) (R2 = 0.946, p < 0.0001).
To explain non-catalyzed polyester hydrolysis, Pitt et al. derived Eq. 7 to describe the







   Equation 7
Fitting Mn degradation data for PBCL1620-PU according to the Eq. 7 (Fig. 9) resulted in
k2 of 1.73 x 10-7 molg-1day-1.
This model does not take into account concentration of ester groups nor water. Lyu et
al. proposed another model to describe the non-catalytic polyester hydrolysis as a
second order kinetic process from which the following first order equation was derived56:
3 s i
1 k C ( t t )
N ( t )
    Equation 8
where N(t) is the number of ester groups that remained in the chain at time t, k3 is the
rate constant [Lmol-1day-1], Cs [molL-1] is water concentration at the moment polyester is
saturated with water, t [day] is the degradation time and ti is the time when polyester is
saturated with water.
If N(t) is calculated according to Eq. 5 and data fitted according to the Eq. 8 (Fig. 9), for
an average water content of 0.6 wt% that is absorbed by PBCL1620-PU sample (4 x 4 x
4 mm3) weighing 0.13 g on average the rate constant, k3, was calculated to be 5.88 x
10-7 Lmol-1day-1. This value is in the same order of magnitude as the rate constant
calculated using non-catalytic model of Pitt et al.58. Disadvantage of both models is that
they neglect auto-catalytic effect of the degradation products.
Figure 9. Linear fit of PBCL1620-PU Mn measured during in vitro degradation assuming non-
catalytic hydrolysis mechanism (according to Pitt et al.58 (R2 = 0.938, p < 0.0001) and Lyu et al.56
(R2 = 0.821, p < 0.0001).
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Recently, a new model has been proposed to describe hydrolytic degradation of high MW
polyesters60, 61. Although this model corrects for crystalline domains present in
semicrystalline polymers, it requires for the initial acid concentration to be larger than
zero, which is not the case with PBCL-PUs.
All mentioned degradation models cannot adequately describe hydrolytic degradation of
polyester urethanes, such as PBCL-PUs of this study. They do not account for hydrolytic
degradation of urethane hard segment in amorphous state and neglect the effect of the
extent of microphase separation. However, they can be used to compare degradation
rate of PBCL-PUs with those of relevant degradable polymers. This analysis revealed that
PBCL1620-PU degrade faster in vitro than PCL-PU of the same oligodiol MW and high
MW PCL. Since both hard segment chemistry and extent of microphase separation were
almost identical, the enhanced hydrolysability of PBCL1620 can only originate from the
introduction of a hydrophilic γ-BL monomer. Furthermore, γ-BL monomer decreased the
PCL oligodiol crystallinity, which might also have influenced accessibility of ester bonds to
hydrolysis.
Recently, we assessed γ-BL/ε-CL-PU manufactured in the same manner as described in
this study for its biological behaviory62. This PU was non-cytotoxic and haemocompatible
in vitro and exhibited good biocompatibility in vivo.
4. Conclusions
The goal of this study was to develop biodegradable PUs with enhanced degradability
that could be used as biomedical scaffolds for tissue regeneration. We successfully
synthesized a range of different molar weight oligodiols via enzymatically-catalyzed, 1,4-
butanediol initiated ROP of γ-BL and ε-CL in a relatively good yield. The oligodiols were
converted into PUs of satisfactory MWs and good mechanical properties. With varying
the oligodiol MW in the PU synthesis it is possible to tailor the materials with the specific
physical and mechanical properties The percentage of incorporated hydrophilic γ-BL in
oligodiols varied from 15 - 26 mol%, which led to the substantial decrease the PCL
crystallinity and improvement of the PU degradation. Employment of the enzymatic
catalyst (Novozyme 435) that could be easily removed from the reaction mixture, a
relatively low-cost γ-BL monomer and conducting the polymerizations at room
temperature make this process attractive for industrial manufacturing of oligodiols
involved in the synthesis of biomedical PUs. Furthermore, PBCL-PUs were shown to be
biocompatible both in vitro and in vivo, which renders this type of PUs excellent
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Tissue engineering and regenerative medicine (TERM) have furnished a vast range of
modalities to treat either damaged tissue or loss of soft tissue or its function. In most
approaches, a temporary porous scaffold is required to support tissue regeneration. The
scaffold should be designed such that the turnover synchronizes with tissue remodeling
and regeneration at the implant site.
Segmented polyester urethanes (PUs) used in this study were based on ε-caprolactone 
(CL) and co-monomers D,L-lactide (D,LL) and γ-butyrolactone (BL), and 1,4-
butanediisocyanate (BDI). In vitro, the PUs were non-toxic and haemocompatible. To
test in vivo biocompatibility, the PUs were further processed into porous structures and
subcutaneously implanted in rats for a period up to 21 days. Tissue remodeling and
scaffold turnover was associated with a mild tissue response. The tissue response was
characterized by extensive vascularization through the interconnected pores, with low
numbers of macrophages on the edges and stroma formation inside the pores of the
implants. The tissue ingrowth appeared to be related to the extent of microphase
separation of the PUs and foam morphology. By day 21, all of the PU implants were
highly vascularized, confirming the pores were interconnected. Degradation of
P(CL/D,LL)-PU was observed at this time while the other two PU types remained intact.
The robust method reported here of manufacturing and processing, good mechanical
properties and in vivo tissue response of the porous P(CL/D,LL)-PU and PBCL-PU makes
them excellent candidates as biomaterials with an application for soft tissue remodeling,
e.g. for cardiovascular regeneration.
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1. Introduction
Acute and chronic diseases may cause permanent changes to the function of organs and
tissues. The physiological repair mechanisms that are induced by the disease are
frequently inadequate. Tissue engineering and regenerative medicine (TERM) are
promising approaches to restore organ or tissue function1-4. TERM attempts to mimic
nature’s own repair mechanisms through the generation of a regenerative
microenvironment. This requires a combination of (stem) cells, instructive factors and a
temporary scaffold. Scaffolds not only model the tissue architecture, but also provide
guidance and adhesive support to cells as well as molar instruction to the cells that are
involved in the regeneration process. In that respect, scaffolds mimic the extracellular
matrix (ECM) and hence should have similar dynamics with respect to its turnover and
physico-chemical features.
Tissue regeneration strategies have been applied to many different soft tissues: nerve
conduits5, cardio-vascular6, 7, skin8, muscle9 etc. All these treatment modalities require
temporary supports i.e. biomedical materials that are tuned to their specific application
in terms of biodegradability, porosity, strength, stiffness and biomechanical
compliance10. Biological compliance puts the chemical and physical processability of
scaffolds to the test, because scaffolds need to facilitate loading with cells and growth
factors and efficient exchange of oxygen, nutrients and waste products. The
development of scaffolds with interconnected pores is challenging because without
adequate fine tuning, the result may be non-patent implants that e.g. lack adequate
vascularization11. Poor scaffold patency also often relates to a limited resorbtion of the
implant in the course of in vivo degradation. In vivo, degradation of scaffolds results
from the inflammation-driven tissue response caused by the implantation of the
biomaterial scaffold. Obviously, the tissue response should be well balanced between
scaffold degradation and tissue regeneration i.e. the degradation should not obstruct or
alter the regeneration, while scaffold turnover should be complete when functional
restoration is achieved. This requires the development of tunable and versatile
biomaterial scaffolds.
Due to their versatility provided by the relatively broad tuning of chemical and physical
properties and an ease of processing into different shapes (homogeneously solid or
porous), PUs represent a promising class of synthetic biomaterials to be applied as
biodegradable scaffolds. In addition to their unique physical properties, PUs have shown
high biological compliance. Several types are used for clinical applications such as
Vialon™ as a IV catheter, Pellethane™ in pacemaker lead insulation and Biomer™ in
cardiac assist devices12. Moreover, Actifit™, a new application of a segmented aliphatic
PU, based on 1,4-butane diisocyanate and poly(ε-caprolactone) has recently arrived in
the market13. The favorable physical property of segmented PUs is the microphase
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separation between soft polyester and hard urethane segments. The microphase
separation is the result of thermodynamic interactions between the segments and should
lead to sufficient immiscibility at lower temperature, to create (at least partial) phase
separation and allow the aggregation and crystallization of the hard urethane
segments14. Taken together, these features provide PUs their appropriate Young’s
modulus which translates into excellent elastic properties and optimal tear strength and
creep. In terms of applications, this renders PUs highly adaptable and applicable e.g. for
cardiovascular TERM.
The aim of this study was to develop and evaluate novel and versatile biodegradable and
haemocompatible PU scaffolds comprising interconnected-pore morphology and for
which the turnover is accompanied by a gradual and mild tissue remodeling at the
implant site. These PU scaffolds should be adaptable to their intended use i.e.
regeneration of vascularized soft tissues, such as of the cardiovascular system, by tuning
the chemical composition and processing parameters.
For hard tissue function restoration like meniscus replacement, PU foams based on
poly(ε-caprolactone) (PCL) and 1,4-butanediisocyanate (BDI) have been developed in
our laboratory13, 15, 16. The implanted PU foams were completely interconnected, caused
only mild inflammatory reaction, and were completely filled with extracellular matrix and
cells of cartilaginous phenotype17. However, similar foams of the same PU were still not
fully degraded a year after implantation18. Slow degradability might be an obstacle to
healthy tissue regeneration when support is needed for a shorter time by causing a
chronic foreign body reaction19, 20.
In the present work, the degradability of PCL/BDI-based PUs was varied by fine tuning
the synthesis parameters for alternative types of PUs based on copolymers of ε-
caprolactone (CL) with γ-butyrolactone (BL) and D,L-lactide (D,LL). The introduction of
these two monomers is expected to enhance the hydrolysis of the polymer chains21, 22.
The copolymer of CL and BL was prepared via an unconventional synthetic pathway,
utilizing an enzymatic catalyst, Candida Antarctica Lipase B, which could easily be
removed from the reaction mixture, rendering the corresponding PU (PBCL-PU) free of
any organometallic catalyst-related biocompatibility issues.
In addition to routine assessment of cytotoxicity parameters, novel PUs were subjected
in vitro to bioburden tests and haemocompatibility assays such as induced thrombin
formation, complement convertase C5 activation and haemolysis. Porous PU scaffolds
were prepared and implanted subcutaneously in rats (for 21 days) to assess the stroma
formation and to asses the dynamics of the degradation.
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2. Materials and Methods
1.1 Polymer synthesis and characterization
In this study, three different PUs were used. They were all based on 1,4-
butanediisocyanate (BDI, Bayer) and 1,4-butanediol (BDO, Aldrich) hard segment. As an
oligodiol soft segment, poly(ε-caprolactone) homopolymer (PCL), ε-caprolactone (Union
Carbide) copolymer with D,L-lactide (Purac) (P(CL/D,LL)) or with γ-butyrolactone (Sigma
Aldrich) (PBCL) were employed. PU synthesis included three steps: 1) oligodiol synthesis,
2) end-capping of the oligodiol with BDI and 3) chain-extension with BDO (Fig. 1). The
oligodiols PCL and P(CL/D,LL) were obtained by BDO initiated thermal polymerization
without the use of any catalysts at 150°C under argon for 7 days23. PBCL oligodiol was
polymerized by a method that will be described elsewhere. Briefly, a mixture of ε-
caprolactone and γ-butyrolactone, freshly distilled toluene (Labscan) and Candida
Antarctica Lipase B (CAL-B, Novozyme-435, Genzyme) was shaken under argon
atmosphere at room temperature for 22 h. Subsequently, chloroform (Acros, p.a. grade)
was added, and CAL-B was removed by filtration through a P4 glass filter. The remaining
mixture was purified under reduced pressure using a Rotavap apparatus and a short
path distillation (Büchi, GKR-50) until a constant mass was reached. The end-capping
and chain-extension procedures were the same for all three polymers23. In short, the
oligodiols were end-capped with BDI in six-fold excess, subsequently the excess BDI was
removed by short part distillation at 80°C until constant mass, and finally, the end-
capped oligodiols were chain-extended with BDO for 16 h at 80°C.
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Figure 1. Synthesis of polyurethanes. Polyurethane synthesis included the following steps: 1)
oligodiol synthesis, 2) end-capping of oligodiol with BDI and 3) chain-extension of prepolymer with
BDO.
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The molar weight of the resulting PUs was measured by gel permeation chromatography
(GPC, Waters 600 Powerline system, C) using dimethylformamide (DMF) with 0.01M LiBr
as eluent at 70°C. Glass transition and melting temperatures were determined by
differential scanning calorimetry (DSC, TA Instruments Q1000). Mechanical properties
were assessed using solvent cast films with a 4301 Instron tensile tester. A Joel 6320 F
Field Emission Scanning Electron Microscopy (FESEM) was used to study the morphology
of porous structures. It was operated at a working distance of 11 mm and acceleration
voltage of 5 kV and beam current of 1 x 10-10 A. The specimens were made conductive
by depositing a 3 nm layer of gold using a Cresdington Rotating Magnetron Sputter
Coater operated at a working distance of 150 mm and a current of 20 mA.
2.2 Processing of PUs
2.2.1. Film casting
Polymer films were prepared by casting a PU solution in dioxane onto PFA Petri dishes
(perfluoroalkoxy polymer resin; Bergof, Florida, USA) at room temperature. After drying,
the films for biological experiments were washed in a Soxhlet apparatus using n-hexane
as the extraction solvent in order to remove any surface contaminants e.g. silicones.
Finally, the materials were dried and stored in vacuo at 40oC until further use.
2.2.2. Foam formation
Foams were prepared by an established method of salt leaching and thermally induced
phase separation16 (Fig. 2). The polymers were dissolved in dimethylsulfoxide (DMSO)
(35 wt% solution). After 2 h of mechanical stirring at 80°C, a small portion of R.O. water
was added (DMSO:water = 30:1 g/g) to decrease the quality of the solvent. Once a
homogeneous mixture was obtained, pre-heated (at 120°C for 1 h) sodium chloride
crystals sieved to a particle size of 50 μm - 90 μm were added to the solution. The 
mixture was homogenized by stirring, poured into a Teflon mold (100mm x 100mm x
2mm), and cooled to -18°C for 2 h. Sodium chloride and DMSO were removed by
extensive washing in a coagulation bath in 20 vol% ethanol solution in R.O. water.
Subsequently, foams were dried under vacuum in an oven at 40°C for at least 24 h.
Finally, the foams were washed in n-hexane.
2.3 Cytotoxicity test and endotoxin level determination
To perform cytotoxicity assay, the fibroblast cell line PK84 was cultured in RPMI medium
(Cambrex Bio Science, Verviers, Belgium) containing 10% FCS (Cambrex Bio Science,
Verviers, Belgium). Cells seeded in a density of 5,000 cells/well were exposed to an
extract of porous PU discs (1 mm thick, 8 mm in diameter) obtained by shaking the
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material overnight in culture medium at 37°C. After 48 h, 20 μl of CellTiter 96® Aqueous
One Solution Cell proliferation Assay solution (Promega Corporation, Madison, WI, USA)
was added to each well and the absorbance intensity was recorded at 490 nm after 90
min of culture. Polyurethane (Pellethane®, Dow Chemical, Midland, MI, USA) and latex
were used as negative and positive control, respectively.
The endotoxin content of the materials was determined by extraction. Briefly, porous
discs (8 mm in diameter, 1 mm thick) were exposed to 1 ml of endotoxin-free water and
shaken overnight at 37C. The extracts were analyzed for their endotoxin content
according to standard procedures (LAL-test).
2.4 In vitro haemocompatibility
The haemocompatibility of PUs was assessed by monitoring thrombin formation,
complement convertase C5 activity and haemolysis. Commonly used reference materials
were included in the experiments.
2.4.1 Thrombin generation assay (TGA)
The formation of thrombin in the presence of the biomaterial was determined by means
of the Thrombin Generation Assay (TGA, Haemoscan, Groningen, The Netherlands).
Polydimethylsiloxane (PDMS; Eriks Alkmaar, The Netherlands) and low-density
polyethylene (LDPE, ET311350 Goodfellow, Cambridge, UK) were used as positive and
negative control, respectively. Thrombin generation was obtained in citrate plasma
depleted of fibrinogen. Materials in the form of films (surface area 0.5 cm2) were
incubated in duplicate in 350 μl plasma in polyethylene tubes for 15 min at 37C. Then
CaCl2 (30 mM) and phospholipids were added, gently mixed and after 1, 2, 4 and 6 min,
10 μl of the incubation mixture was diluted in 490 μl of ice-cold 25 mM TRIS-HCl buffer 
to stop further thrombin formation or inhibition. These diluted samples were incubated at
37C with 3 mM thrombin chromogenic substrate S2238 (Chromogenix, Milano, Italy) for
20 min. The optical density of the yellow color was measured at 405 nm in a micro titer
plate reader (Powerwave 200 Bio-Tech Instruments, Winooski, Vermont). A calibration
curve was constructed with known concentrations of thrombin in TRIS buffer.
2.4.2 Complement convertase C5 activity
Surface-bound C5 convertase was determined on 1 cm2 PU films after incubation in
porcine plasma for 15 min at room temperature. (CCA, Haemoscan, Groningen, The
Netherlands). After incubation, the samples were rinsed and incubated in chromogenic
substrate S2527 (Chromogenix) diluted in TRIS buffer at room temperature in the dark for
24 h. Thereafter, the optical density was determined at 405 nm in a microplate reader.
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2.4.3 Haemolysis test
PU films (total surface 1 cm2 per sample) were incubated for 24 h in whole citrate
anticoagulated blood mounted on a rotator at 37oC. Medical grade stainless steel (316L;
Goodfellow) and copper (Goodfellow) were used as negative and positive control,
respectively. Total and free hemoglobin concentrations in plasma samples collected
before and after incubation were determined using the direct optical method of
Harboe24. The samples were diluted 10-fold with 0.01 % Na2CO3. Upon 30 min of
incubation at room temperature, the optical density at 380, 415 and 450 nm was
measured.
2.5 In vivo study of PUs
To investigate the tissue response of PCL-PU, PBCL-PU and P(CL/D,LL)-PU porous discs
were implanted subcutaneously in the back of rats.
Discs (1 mm thick, 8 mm in diameter) were sterilized by incubation in 70 vol% ethanol
solution for 24 h followed by rinsing twice for 4 h in PBS buffer. The discs were dried and
preserved in a closed glass container before the experiments. Animal experiments were
carried out according to the National Institutes of Health (NIH) guidelines for the care
and use of laboratory animals (NIH Publication No. 85-23, Rev. 1985). Male Wistar rats
of ~ 3 months of age were anesthetized with a mixture of halothane, N2O and O2. After
shaving and disinfection, subcutaneous pockets were made to both sides of two 1-cm
midline incisions on the back of the rat. Discs were placed in the pockets and implanted
for, respectively 3, 10 and 21 days (n = 5). After surgery, the rats were housed in a
temperature- and humidity-controlled room with 12 h light/dark cycles and access to
water and standard rat food ad libitum. At predetermined times, rats were anesthetized,
and implants with the surrounding tissue were carefully ex-planted. Each disc was cut in
half - one piece was further fixed in formaldehyde and analyzed for histology, and the
other piece was snap frozen in liquid nitrogen and kept at - 80°C until it could be used
for immuno-hystochemistry.
2.5.1 Light microscopy
For plastic embedding, the glutaraldehyde fixed materials were dehydrated in graded
alcohol dilution series and longitudinal regions were embedded in Technovit 7100
(PolyHEMA, Heraeus Kulzer, Wehrheim, Germany) according to the manufacturer’s
protocol. Sections of 2 μm were stained with toluidine blue (Fluka Chemie, Buchs, 
Switzerland) and analyzed by light microscopy. Light microscopy evaluation was carried
out with a Leica DM-LB microscope (Leica, Rijswijk, The Netherlands) using Leica Qwin
2.3 software to obtain photomicrographs. The software was further used for
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morphometrical analysis of the extent of tissue ingrowth as a percentage of the total
cross-sectional area (n = 3 explants (sections) per polymer per time point; 6 images per
section).
2.5.2 Immunohistochemistry
For immunohistochemical evaluation, longitudinal sections (7 µm) from snap-frozen
explants were cut at – 25°C and fixed with acetone. For the detection of macrophages
and giant cells, the sections were pre-incubated with 10% rabbit serum and incubated
with mouse-anti-rat ED-1 (Serotec Ltd, Oxford, UK). Blood vessels were detected by pre-
incubation with 10% goat serum and subsequent incubation with goat-anti-human-
collagen type IV (Southern Biotechnology Associates Inc., Birmingham, USA) which
cross-reacts with rat collagen type IV. Collagen III was detected by incubation with anti-
mouse coll III (Abcam, Cat.n. ab310-100). This was followed by H2O2 treatment to
remove endogenous peroxidase activity and subsequent incubation of the slides with
rabbit-anti-mouse-peroxidase (for ED-1 and coll III) or rabbit-anti-goat-peroxidase
(Dako, Glostrup, Denmark), stained with 3-amino-9-ethylcarbazole (AEC, Sigma,
Steinheim, Germany) and counterstained with Mayer’s hematoxylin (Fluka Chemie,
Buchs, Switzerland).
3. Results
3.1 Properties of PUs
In the present study we compared our new PUs with the PUs based on the same hard
segments and pure oligo ε-caprolactone diol. This polymer has been studied extensively
in our group for application as a scaffold for meniscus regeneration16. The degradation
profile of this PU, however, is not considered to be suitable for scaffolds intended to be
used for soft tissue regeneration. Therefore, modifications of the PU were needed to
fulfill the requirements for this type of application. While maintaining the requirement of
microphase separation, we modified the oligodiol by incorporating other co-monomers,
which are expected to enhance the degradation time without compromising other
properties. Therefore, in the present study a PU with the same PCL-oligodiol molar
weight (1000 g/mol) was used as a reference material for comparison of the thermal
properties23.
As can be seen from Table 1, all three PUs (PCL-PU, PBCL-PU and P(CL/D,LL)-PU) were
microphase-separated systems. However, it is also clear from the ΔHm values that
incorporating the co-monomers (25 mol% of BL in PBCL-PU, and 10 mol % of D,LL in
P(CL/D,LL-PU) decreased the crystallinity and extent of microphase separation.
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Table 1. Characterization of polyurethanes. Polyurethanes were characterized for molar weight
(Mn, Mw) and polydispersity (D), thermal (Tg, Tc, Tm and ΔHm) and mechanical properties (tensile
strength, maximum strain and Young’s Modulus). HSC - hard segment content, AA - amorphous
hard segment assumption, CA - crystalline hard segment assumption, CHS - hard segment
crystallinity All the three PUs were microphase-separated systems. Introduction of co-monomers
(25 mol% of BL in PBCL-PU and 10 mol% in P(CL/D,LL)-PU) decreased the hard segment
crystallinity and the extent of microphase separation.
Polymer property PCL-PU PBCL-PU P(CL/D,LL)-PU
Mn (g/mol) 91000 65000 21000
Mw (g/mol) 225700 151600 10900
D 2.48 2.33 1.94
Tg (°C) -43.1 -47.2 -43.6
Tc (°C) 73.6 9.2 -4.1
Tm (°C) 113.3 100.5 81.3
ΔHm (J/g) 35.5 22.86 12.3
HSCTH 0.27 0.21 0.27
CHSCA* (%) 67 56 23
CHSAA *(%) 61 51 21
Tensile strength (MPa) 31.6±1.5 13.4±1.0 29.4±4.9
Max. strain (%) 1140±81.0 439±65 631.2±121.5
Young’s Modulus (MPa) 99.3±15.9 81.8±10.5 42.9±10.0
* Calculated from DSC data based on Heijkants et al23.
This inevitably led to lower values of the modulus and tensile strength, although this
latter property might also be affected by the somewhat higher molar mass of the
oligodiol used: PCL-PU and P(CL/D,LL)-PU were based on a 1,000 g/mol oligodiol length,
whilst the molar mass of the PBCL oligodiol was 1,450 g/mol.
The crystallization temperature (Tc) was very different for the three PUs. This affected
their processability into foams. The Tc of PCL-PU (73.6°C) was close to the processing
temperature (80°C). Therefore, the crystallization interfered with the foam-formation
process.
Based on the measured ΔHm and a value for the melting enthalpy of a theoretically 100
% crystalline hard segment, one can calculate the crystallinity of the current materials23.
From Table 1 it is obvious that the PUs differed greatly in crystallinity that may impact
their degradation in vivo.
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3.2 Preparation of porous structures
The morphology analysis by SEM of the porous discs prior to implantation showed
structures with uniformly distributed pores that were interconnected (Fig. 3). The
porosity of all the foams was approximately 87 % based on gravimetrical results (data
not shown). Unlike PBCL-PU and P(CL/D,LL)-PU, which showed open pore structures, the
PCL-PU foam appeared to be more closed and consisted of 10 μm spherical structures. 
Scanning electron micrographs of the PBCL-PU foam showed the existence of two
different types of pores - larger (50 μm on average) made as an imprint of porogen 
particles, and smaller (up to 10 μm) originating from the freezing and subsequent 
migration of the solvent.
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Figure 3. Scanning electron microscopy of PU-foams before implantation (cross-section). A) PCL-
PU, PBCL-PU and C) P(CL/D,LL)-PU.
3.3 Cytotoxicity test and endotoxin level determination
Mitochondrial activity of PK-84 cells cultured in the medium containing extracts from the
tested PUs was used as a measure of material cytotoxicity. All tested PUs were non-
cytotoxic, as the cell survival was comparable to negative control (Table 3). Furthermore,
the level of endotoxin was for all tested PUs < 20 EU per polymer.
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Table 3. Cytotoxicity and endotoxin level determination. Cytotoxicity of PUs was comparable
to clinical grade polyurethane Pellethane®. Latex was used as a positive control, while medium
served as the negative control (n=4, data expressed as average±SD). Endotoxin level was
measured by the LAL-test (n=1).
Test material Cell survival (%)
Endotoxin level
(EU/ml)






*n.d. - not done
3.4 Haemocompatibility
All three PUs showed excellent results in various in vitro haemocompatibility tests as
revealed by low thrombin formation, low complement convertase C5 activity, and
negligible haemolysis (Fig. 4). The speed of thrombin generation induced by all three
PUs was less than low-density polyethylene (LDPE) which is considered mildly
thrombogenic.
Regarding the activity of surface-bound complement convertase C5 as a measure for the
activation of the complement cascade, all three tested PUs minimally activated
complement compared to other biomedical materials.
Contact of PUs with citrate anticoagulated blood resulted in very low free haemoglobin
content (far below 1g/L as considered haemolytic) indicative of minor damage to the red
blood cells.
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Figure 4. In vitro haemocompatibility of polyurethanes. A) Thrombin generation assay (TGA), B)
Complement convertase C5 activity (CCA) and C) Haemolysis test. Control materials used for
comparison: polydimethylsiloxane (PDMS), low-density polyethylene (LDPE), stainless steel (SS)




The tissue response to subcutaneously implanted PUs (PCL-PU, PBCL-PU and P(CL/D,LL)-
PU) as potential biomaterials with temporary scaffold function was monitored for up to
21 days. Overall, at day 3 the cellular ingrowth and accompanied extracellular matrix
(ECM) deposition in all PUs was marginal (Fig. 5). Fibrin deposition onto the edges of the
pores of the PUs was present in all three PU implant types and was most abundant in
PBCL-PU. In general, cellular influx proceeded from the edges of the implant to the
centre, and was characterized by infiltration of macrophages and fibroblasts. At day 10,
a thin capsule surrounded all the implants. PCL-PU showed the highest tissue ingrowth
(50 %), compared to PBCL-PU (20 %) and P(CL/D,LL)-PU (30 %) (Fig. 5). Tissue
ingrowth was characterized by stroma formation inside the pores (i.e. formation of ECM
and blood vessels). The largest ingrowth was observed with P(CL/D,LL)-PU.
Furthermore, at the edges of the infiltrated pores some giant cells had been formed.
Lymphocytes were only sporadically present within P(CL/D,LL)-PU implants.
Figure 5. Tissue ingrowth through the polyurethanes. Statistical analysis was performed by two-
way ANOVA followed by Bonferroni post hoc analysis using GraphPad Prism software v4 (San
Diego, California, USA). Values of p < 0.05 were considered statistically significant. (n=3; 6 images
per slide, data expressed as mean ± standard error of the mean).
At the end of the assessment period (day 21), the explants were still characterized by a
thin encapsulation while stroma and giant cells had formed inside the pores (Fig. 6, Fig.
7 and Fig. 8). P(CL/D,LL)-PU discs were almost completely filled with stroma (90 % on
average), while in the other two PUs approximately 30 % of the available pores had not
been infiltrated (Fig. 5).
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In contrast to PCL-PU (Fig. 7) and PBCL-PU (Fig. 8), single cells (macrophages and giant
cells) were not only located at the interface, lining the pores, but had infiltrated
P(CL/D,LL)-PU material, suggesting that degradation had started (Fig. 6). Therefore, day
21 explants were analyzed in more detail for the presence of macrophages, ECM and
angiogenesis by immunohistochemical staining.
Figure 6. Cross-sections of the tissue response to P(CL/D,LL)-PU at day 21.
a-c: Toluidine blue staining, d-f: immuno-histochemistry for macrophage (ED1) detection, collagen
III and blood vessel (collagen IV) respectively; pores are lined. Many scattered macrophages
(arrows) and some giant cells (G) infiltrated P(CL/D,LL)-PU (fig. a and b) as shown by ED1 staining
(fig. d). Giant cells were observed intruding the pores from the side of the material (fig. b),
indicating material degradation. ECM deposition (S) was clearly present around large blood vessels
(*) throughout the material (fig. a and e). Vasculature (*) was highly developed (fig. a, c and f)
and functional (fig. c - large blood vessel with erythrocytes).
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As can be seen from Fig. 6d, macrophages and giant cells penetrated the insides of the
P(CL/D,LL)-PU, indicating that at least a part of P(CL/D,LL)-PU had been degraded.
Large blood vessels were interconnected in the pores, but did not cause a collapse of
P(CL/D,LL)-PU (Fig. 6c and f). Collagen III deposition was also restricted to the pores of
the material (Fig. 6a, c and e). These observations indicate a beginning of gradual
degradation of P(CL/D,LL-PU) with maintenance of the interconnected stroma in 90 % of
the material.
The pores of PCL-PU (Fig. 7f) were filled with many small blood vessels (Fig. 7a and c)
embedded in mainly collagen III containing ECM (Fig. 7a and e). Macrophages were
lining the pores of PCL-PU (Fig. 7d) and only some giant cells were stretched out on the
edges of pores of PCL-PU (Fig. 7b), which was confirmed by light microscopy.
Figure 7. Cross-sections of the tissue response to PCL-PU at day 21.
a-c: Toluidine blue staining, d-f: immuno-histochemistry for macrophage (ED1) detection (depicted
with an arrow), collagen III and blood vessel (collagen IV) respectively; pores are lined. The pores
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of PCL-PU were thoroughly occupied with rat tissue (fig. a). Giant cells (G) and macrophages
(arrow) were lining the pores of the material (fig. b) and blood vessels (*) were present
throughout the pores (fig. a, c and f). ECM (S) occupied the pores (fig. a and e).
With PBCL-PU, collagen IV staining (Fig. 8f) revealed that many functional blood vessels
(containing erythrocytes) infiltrated the pores (Fig. 8a and c). Compared to PCL-PU, ECM
deposition in the pores of PBCL-PU was less pronounced (Fig. 8a and e). Similar to PCL-
PU, cellular activity (mostly giant cells) was directed toward the edges of PBCL-PU pores
(Fig. 8b and c).
Figure 8. Cross-sections of the tissue response to PBCL-PU at day 21.
a-c: Toluidine blue staining, d-f: immuno-histochemistry for macrophage (ED1) detection, collagen
III and blood vessel (collagen IV) respectively; pores are lined. Many small functional blood vessels
infiltrated the pores of PBCL-PU (fig. a and c) as confirmed by collagen IV staining (fig. f). The
pores of PBCL-PU were lined with macrophages (fig. d) and giant cells (G; fig. b and c). Collagen




In this study, we explored novel biodegradable PUs that were haemocompatible in vitro
and also showed mild in vivo tissue response. Upon 21 days of implantation, the PUs had
completely integrated into surrounding tissue and were extensively vascularized
throughout their interconnected porous structures.
In the synthesis of PBCL-PU, an enzymatically catalyzed oligodiol was employed. This
oligodiol was successfully prepared by BDO initiated ring-opening polymerization of CL
and BL via enzymatic catalysis with CAL-B (data will be published elsewhere). The
utilization of CAL-B made polymerization of BL, a low ring strain25 and thus low reactive
lactone possible. Furthermore, the reaction time was shortened (reacted for 22 h at
room temperature) compared to the long lasting thermal polymerization of PCL
conducted at elevated temperatures (7 days at 150°C)23. In contrast to other
organometallic catalysts (e.g. Stannous Octanaoate) that remain in the biomaterial,
presenting a health risk after implantation, CAL-B can be easily removed from the
reaction mixture at the end of the synthesis. Since PUs are considered superior to
polyesters in terms of their mechanical properties and biological performance26, this
approach of applying oligo-esters made by different usually chemically non-polymerizable
monomers could open the door to a variety of novel biomedical PUs. To our knowledge,
this is the first time a PU based on a soft BL/CL segment and hard BDI-BDO segment
have been prepared and its biological responses assessed in vitro and in vivo.
The PU synthesis was conducted in the same manner for all three PUs, yet they were
comprised of oligodiols with different molar weight and chemical composition. Thus, the
resulting PUs exhibited different degrees of microphase separation and variable
mechanical properties. These physical characteristics had a strong impact on the
processability of the PUs. Application of the foam-forming process developed by
Heijkants et al.15, led to the open foam structure. Essentially, this is a combined
procedure of salt-leaching and thermally induced phase separation. However, the
physical properties of the three different PUs resulted in somewhat different foam
appearance even though the ratio of the components in foam-forming process was
identical. PCL-PU was organized into spherical structures, probably due to the
interference of the PCL-PU crystallization (via the mechanism of nucleation and growth)
with the foam-formation process. This phenomenon has also been observed by Heijkants
et al.16. P(CL/D,LL)-PU pores appeared smaller and more closed. From the three PUs
tested, P(CL/D,LL)-PU was characterized by the lowest molar weight, lowest degree of
phase separation and the poorest mechanical properties. This made P(CL/D,LL)-PU more
sensitive to handling and SEM sample preparation effecting the SEM image.
The most striking benefit of using a combined salt-leaching thermally induced phase
separation method is the interconnectivity of the resulting porous PU scaffold structure.
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The observed interconnectivity by SEM was confirmed by the in vivo findings by
abundant vascularization of the PUs at the day 21 of implantation, especially in
P(CL/D,LL)-PU. In addition, the investigated PUs supported fibroblast and human
umbilical vein endothelial cells (HUVEC) adhesion (data not shown), which makes them
attractive candidates as tissue engineered scaffolds. In both situations, either
implantation of a bare scaffold, or pre-seeded tissue engineered construct, the presence
of the functional vasculature is considered essential in resorbtion of scaffold degradation
products and survival of pre-seeded cells27.
The results of the in vivo study showed higher tissue infiltration and stroma formation in
the PUs with the modified soft segment (PBCL-PU and P(CL/D,LL)-PU). With the
introduction of more hydrolysable soft segment components, it is expected that the
surface hydrophobicity would decrease, hence providing favorable surface properties for
cell adhesion28 and faster degradation. As shown by Hunt et al., the increase in the
hydrophobicity resulted in the higher influx of macrophages at the early stages of
implantation29. However, after 1 month of implantation the macrophage response was
similar for all the materials tested, regardless of their hydrophobicity. Furthermore,
Christenson et al. showed that the change in soft segment chemistry of PUs did not
influence monocyte/macrophage adhesion in vitro30. The cell influx and ECM deposition
onto the PUs could be related to their physical properties. Less microphase-separated
and at the same time less stiff PUs showed to be readily infiltrated with cells and
exhibited faster stroma formation. In the case of PCL-PU, the porous structure was the
most closed of the three. This finding corresponded to the lowest degree of tissue
ingrowth in the case of PCL-PU. Hilborn et al. propose that the mechanical properties of
the interface between an implant and its surrounding tissue rather then the chemical
composition governs the performance of the implant31. Thus, the observed difference in
the morphology and mechanical properties of all three PUs used in this study may have
affected the observed in vivo tissue response.
The degradation at day 21 of implantation could only be observed in foams prepared
from P(CL/D,LL)-PU. The degradation of PUs in vivo depends on the extent of
microphase separation32. Since crystals are non-permeable for water molecules,
hydrolytic and/or enzymatic degradation (e.g. by cholesterol esterases, carboxyl
esterases and /or matrix metalloproteinases), could only take place in the amorphous
domains of PUs containing mixed amorphous soft and hard segments. This is also shown
by Santerre et al.33 According to the values for hard segment crystallinity, P(CL/D,LL)-PU
(~ 22%), as expected, degraded the fastest of the three PUs studied compared to e.g.
PCL-PU (~ 65%). For biomedical applications where the tissue regeneration is slower
than 21 days, PBCL-PU could be a good candidate.
Chapter 5
112
Figure 9. Fabrication of porous tubular structures. A - mold; B - porous PU rod; C - wire-heating
method for creating the closed graft inner surface; D - SEM of the tube cross-section.
The robust method of manufacturing and processing, good mechanical properties and in
vivo tissue response of the porous P(CL/D,LL)-PU and PBCL-PU from this study makes
them excellent candidates as biomaterials, e.g. for (cardio)vascular regeneration. An
example of how the PUs could be processed into scaffolds for vascular replacement is
depicted in Fig. 9. The porous hollow cylindrical constructs were prepared by
manufacture of porous rods and a subsequent wire-heating step, in order to close the
pores from the luminal side by partial melting of the PU foam. This method would
provide a blood conduct that could be integrated with the surrounding tissue via the
other porous layer. Gradually, the porous structure would become vascularized,
facilitating the traffic of cell nutrients and metabolites and PU degradation.
5. Conclusions
Easily processable novel PUs presented in this study were not only biocompatible in vitro,
but also evoked only a mild in vivo tissue response. Already after 21 days of
implantation, the porous PU scaffolds had fully integrated into the surroundings and
were extensively vascularized. In this relatively short period, degradation of one of the
PUs, P(CL/D,LL)-PU has been observed. This PU could be employed as a short-term
biodegradable scaffold in soft tissue (e.g. blood vessel) remodeling.
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1. Introduction
Most of the regeneration therapies to treat damaged or lost soft tissues depend on the
use of biodegradable scaffolds. A successful scaffold should provide a structural support
whilst remaining transient until functional restoration is achieved. Tissue restoration and
function recovery can only be achieved if biomaterial degradation and physiological
turnover are balanced. If degradation rate of a scaffold is higher than the rate of tissue
regeneration, the prerequisite mechanical support would be lost. In addition, rapid
degradation might cause build up of degradation products locally and could lead to a
severe tissue response. Slowly degrading scaffolds on the other hand, may lead to
impairment of optimal regeneration seen as a late tissue reaction1, 2.
In this thesis, we focused on design of scaffolds that could be utilized as a basic
component in soft tissue treatment therapies. More specifically, the aim of this thesis
was to design biocompatible scaffolds for soft tissue regeneration that are expected to
gradually degrade within a year evoking mild tissue response.
The tunable mechanical properties and the ease of processing that do not affect their
generally good biocompatibility render segmented polyester urethanes (SPEUs) attractive
as biodegradable biomedical materials. Due to the so-called “soft segment” block based
on oligoesters, SPEUs are prone to degradation primarily via hydrolysable ester
functionality. Biodegradable SPEUs based on poly(ε-caprolactone) (PCL) oligodiol and
1,4-butanediisocyanate (BDI) were developed within our research group and were
successfully applied in meniscus replacement3,4, 5. Although suitable as long-term
implants, the degradation of these materials had to be enhanced before they could be
applied in regeneration of soft tissues. Tunability of SPEUs allowed us to increase
susceptibility of these SPEUs to hydrolysis via chemical modification of either polyester
soft segment or by introducing more reactive (and hydrolyzable) hard segment.
In this thesis, to increase hydrolyzability of BDI-based SPEU, we modified PCL soft
segment by incorporation of co-monomers (γ-butyrolactone: γ-BL and D,L-Lactide: D,LL)
(Chapters 4 and 5) . Hard segment hydrolysability of PCL-based SPEU was enhanced by
incorporation of on terephthaloyl diisocyanate (TPHDI) in the hard segment (Chapter 2).
Since these novel SPEUs were intended as temporary scaffolds in regenerative medicine,
we assessed their cyto- and haemocompatibility in vitro (Chapters 3 and 5).
For full integration with the surrounding tissue, a scaffold should allow for migration of
cells, nutrients and products of cell metabolism and angiogenesis. Therefore, for soft
tissue regeneration, employment of porous scaffolds with interconnected channels is a
necessity6, 7. Based on a combined salt leaching/thermally induced phase separation
method previously developed in our laboratory8, we prepared such scaffolds from novel
SPEUs and tested their biocompatibility in vivo (Chapter 5).
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In the following sections we will discuss our findings on biological performance of the
novel SPEUs in respect to their chemical composition and scaffold properties.
2. Enhancing degradation of segmented polyester urethanes
2.1 Hydrolysis of segmented polyester urethanes
It is generally accepted that the hydrolytic degradation of SPEUs proceeds via a random
scission of ester bonds of a soft segment following a bulk degradation mechanism9, 10.
According to this mechanism, molecular weight of SPEU is expected to gradually
decrease with degradation whilst the mass of SPEU should remain unchanged11. The
extent of hydrolysis depends on specific ester group susceptibility to hydrolysis and
water diffusability through the SPEU matrix. The latter is retarded by presence of
crystals, either of polyester soft segment or hard segment crystallinity. Upon
degradation, cleaved components (i.e. acids, alcohols and amines) diffuse through the
polymer to the surroundings. However, if SPEU is not preferentially surface degraded,
the degradation products remain trapped in bulk, which further causes accelerated
degradation (so-called autocatalytic effect)12, 13. Furthermore, the diffusion of the
degradation products is mainly governed by their solubility in water. As chains are
cleaved, the mobility of remaining part of a chain increases. During PCL hydrolysis, this
can in turn result in re-crystallization as observed by Pêgo et al.14, Lam at al.15 and
Antheunis et al.16
Due to the microphase separated morphology (Chapter 1), hydrolysis of SPEU cannot
adequately be described by applying the same models established for hydrolysis of semi-
crystalline high molecular weight polyesters, such as PCL12. Depending of the degree of
microphase separation, SPEU also contains a (urethane) hard segment in an amorphous
state. Due to higher polarity of the urethane, these amorphous portions undergo
hydrolysis as well, which contributes to the overall degradation of SPEUs.
To summarize, the overall degradation of SPEU involves both hydrolysis of the polyester
soft and hard segment in an amorphous phase of the SPEU. In addition to possibility to
tailor degradation by a choice of the SPEU building blocks (co-monomers, diisocyanate),
varying the degree of microphase separation of SPEU provides an additional tool in
tuning the degradation.
2.2 Soft segment modification
As expected, an introduction of hydrophilic γ-BL monomer to the PCL soft segment
resulted in SPEUs (PBCL-PUs) that degraded faster in vitro than corresponding SPEU
based on (homo) PCL (PCL-PUs) (Chapter 4). This was observed by twice as high
hydrolysis rate than in case of PCL-PUs as observed by Heijkants et al.8 and detection of
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mass loss even in a relatively short degradation period (Chapter 4). Although in both
SPEUs soft segment was amorphous before degradation has taken place, crystallization
of PBCL soft segment in the course of degradation was less likely to occur than re-
crystallization of PCL. In addition, being more hydrophilic than ε-CL, γ-BL could more
readily diffuse out of the polymer. The observed mass loss indicated that PBCL-PUs
degraded partially by surface erosion mechanism too. Compared to another typically
surface eroding biopolymer, poly(trimethylene carbonate) (PTMC), PBCL-PUs lost their
mass much faster14.
Pure poly(D,L-Lactic) acid looses its mechanical properties after 1 – 2 months and is fully
degrades after 12 – 16 months in vivo17. Introduction of D,L-Lactide into the soft
segment of SPEU should mainly disturb the crystallinity of PCL, thus resulting in faster
degradation. Indeed, during the course of our study (21 days) P(CL/D,LL)-PU was the
only polymer to degrade in vivo (Chapter 4). This will be further discussed in section 3.2
of this chapter.
2.3 Hard segment modification
In Chapter 2 we showed that an introduction of a more reactive diisocyanate
(terephthaloyl diisocyanate, TPHDI) and lower degree of microphase separation of PAUs
than the corresponding BDI-based SPEU resulted in the mass loss of 2. 7 – 4.0 % over
80 days of degradation with the decrease of the number average molecular weight (Mn)
of ~ 35 %. When Mn data were plotted assuming autocatalytic ester (soft segment)
hydrolysis, an exponential instead of linear decay was observed. To our knowledge, this
was never observed before with degradation of SPEUs. The main reason for this
enhanced degradation lies in the fact that TPHDI-based hard segment hydrolyses
relatively fast18 and that most of the hard segment was amorphous (Chapter 2).
Being potential biomedical polymers, biocompatibility of these novel SPEUs had to be
assessed before they could be considered as polymers in soft tissue regeneration
applications. Next to basic cytotoxicity and endotoxin level assessment, we focused on
haemocompatibility, cell adhesion and proliferation (in vitro) and tissue response (in
vivo).
3. Biological performance
3.1 Protein deposition and cell adhesion
Besides hydrolysis features of biomaterials, their surface properties will mainly determine
their biocompatibility. After all, it is the surface of biomaterials which may comprise of
only a few molecular layers, that the cells will encounter and respond to.
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Surface properties, especially surface hydrophylicity, of biomedical materials to be used
as temporary scaffolds determine protein adsorption and cell adhesion. The optimal
surface contact angle for cell adhesion is 60° 19, 20. In addition to hydrophilicity, presence
of functional groups that are recognized as ligands further promotes cell adhesion.
Due to microphase separation, SPEUs exhibit dynamic surface properties. Depending on
the surroundings, the chemical composition of the surface of SPEU comprises more of
soft (hydrophobic) or hard (hydrophilic) segments21, 22. The latter caused an increase in
hydrophilicity of the PAU1000 surface (Chapter 3). Upon incubation with serum proteins,
the contact angle decreased to 60° after only 18 hours (Chapter 3). We showed that the
hydrophilicity of the PAU1000 also increased with degradation as a result of the
preferential surface chain scission and formation of polar groups (Chapter 2).
In general, PUs do not provide optimal support for cell adhesion. Voskerician et al.
showed that low cell adhesion of PUs can be explained by dominant presence of
generally considered non-adhesive plasma proteins such as albumin, high-density
lipoprotein and high molecular weight kininogens (HMWK), which all do not favor cell
binding23. In order to enhance adhesion of HUVEC, we coated PAU1000 with fibronectin
(Fn). Although Fn was initially shown as beneficial for HUVEC attachment, in later stages
(after 8 h of culture) the number of adhered HUVEC on Fn-coated PAU1000 firstly
decreased until a Fn-coating effect was diminished (Chapter 3). Even though the rate of
HUVEC adhesion may appear low, longer incubation experiments (25 h) revealed that
both bare PAU1000 and Fn-coated PAU1000 allowed for significant HUVEC proliferation.
This proliferation rate is expected to be sufficient to e.g. generate an anti-thrombogenic
cellular coating in tissue engineered blood vessels. We expect that other cell types, e.g.
fibroblasts, would respond similarly to HUVEC, thus marking PAU1000 adequate for other
soft tissue TERM application, e.g. skin regeneration.
Thus, the surface of a particular SPEU intended for biomedical application should be
thoroughly characterized both bare and in interaction with plasma proteins. Obtained
results would not only serve as an indication of the protein deposition and closely related
cell adhesion to SPEUs in vivo, but could guide us how to manipulate SPEU surface to
achieve desired cellular response (by e.g. surface modification).
3.2 Tissue response
A successful biodegradable scaffold degrades harmoniously with tissue regeneration and
causes only mild tissue response. Mild tissue response is characterized by low leukocyte
infiltration and a relatively thin fibrous capsule formation around the implant.
Macrophages and formed giant cells should be able to absorb and process the
degradation products released from the degrading scaffold. In vivo degradation of any
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degradable biomaterial always involves the action of inflammatory cells which
superimposes on the chemical hydrolysis of the scaffold.
Chemically spoken, the tissue response to SPEU is a result of interplay of three elements:
1) SPEU chemical composition and surface properties, 2) extent of microphase
separation and 3) scaffold morphology (i.e. pores size, uniformity and interconnectivity).
It can be anticipated that the influence of SPEU chemical and surface properties and the
extent of microphase separation to tissue response would be comparable to their
behavior in vitro, which was discussed previously (Chapters 2, 3 and 5). In short, SPEU
based on more hydrolyzable and hydrophilic monomers and diisocyanates that exhibit
relatively low extent of microphase separation and more hydrophilic surfaces were
expected to result in higher cell adhesion and degrade faster in vivo.
We employed a combined method of salt leaching and thermally induced phase
separation to yield porous scaffolds from soft segment modified SPEUs (Chapter 5;
P(CL/D,LL)-PU and PBCL-PU). As reported by Heijkants et al., the most striking benefit of
using this processing method is the interconnectivity of the resulting porous PU scaffold
structure24. The interconnectivity of the pores is also a prerequisite for scaffold
vascularization in vivo which is essential for tuned resorption of biodegradable scaffolds
by macrophages and/or giant cells and concomitant tissue regeneration25. The
interconnectivity shown by scanning electron microscopy was confirmed by throughout
vascularization of the SPEUs at the day 21 of implantation, especially in P(CL/D,LL)-PU.
Scaffold morphology determines availability for tissue ingrowth. Manufacturing of porous
scaffolds from the unmodified SPEU, PCL-PU, yielded less homogeneous porosity that
was characterized by the lower degree of tissue ingrowth.
As expected, SPEUs with the modified soft segment with lower degree of microphase
separation exhibited a higher degree of cell infiltration, stroma formation and
degradation than SPEU based on unmodified, PCL-PU (Chapter 5). The degree of tissue
ingrowth into the tested PUs was observed to decrease in the following order:
P(CL/D,LL)-PU > PBCL-PU > PCL-PU.
Hilborn et al. proposed that the mechanical properties of the interface between an
implant and the surrounding tissue rather than chemical composition govern the in vivo
performance of an implant26. Mechanical properties are a direct consequence of the
extent of microphase separation and were as anticipated poorer in the PUs with lower
microphase separation (Chapter 5). Since P(CL/D,LL)-PU was the least strong of the thee
tested SPEUs, it led to the highest degree of tissue ingrowth (Chapter 5).
In order to determine which of the elements (chemistry, extent of microphase separation
or scaffold morphology) predominantly influenced SPEU behavior, it is important to
consider the time scale (sequence) of events involved in the tissue response for the
studied SPEUs (Fig. 1). As depicted in Fig. 1, biological processes of protein deposition
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on a biomaterial surface, cell adhesion and vascularization proceeded much faster than
SPEU degradation. Therefore, tissue response was determined by the initial SPEU
properties and not by material bulk and surface change upon hydrolysis. Although
proven beneficial in enhancing SPEU degradation, chemical modification of the soft
segment is not expected to influence tissue response in the short term, i.e. before the
degradation of the SPEU occurs. Although not assessed, surface hydrophobicity of the
PUs used in the in vivo study was assumed to be comparable. Therefore, determining
factors influencing the initial tissue response (studied up to 21 days) were the extent of
microphase separation and the scaffold morphology.
Figure 1. Sequence of events tissue response to soft segment modified PUs.
In the case of our SPEUs that do not possess any biologically derived reactive functional
groups such as integrin ligands (e.g. RGD motifs) and are only slightly chemically
different, the surface chemistry cannot be a discriminating factor causing different stages
of the (short-term) tissue response.
4. Degradation of the novel SPEUs - summary
By changing the chemical constituents, we developed SPEUs with different mechanical
properties. These were determined by the molecular weight of the SPEUs and the extent
of microphase separation. SPEUs exhibiting a lower extent of microphase separation
possessed poorer mechanical properties. As already discussed, the extent of microphase
separation further determined degradation rate by influencing water diffusion through
the SPEU matrix and accessibility of ester and urethane groups to water. Thus, an extent
of microphase separation has to be chosen in such a way that it allows for hydrolysis but
it does not impair the mechanical properties of the SPEU scaffold.
From the results in vitro, PAU1000 hydrolyses the fastest of the assessed SPEUs. We
speculate that this SPEU would degrade at least as fast in vivo. PAU1000 showed
substantial hydrolysis in vitro at 20 days already. It is possible that this relatively fast
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degradation would influence tissue response. Therefore, the tissue response and the
long-time (at least 6 months) degradation in vivo should be investigated.
When all the SPEUs described in this thesis were compared for degradation, the
following trend was observed: PAU1000 = P(CL/D,LL)-PU > PBCL-PU > PCL-PU (Fig. 1).
Here, only one polyurethane per SPEU type was used in the comparison. Using
polyurethane chemistry it is possible to manufacture a whole range of SPEUs with
different oligodiol (soft segment) length that would degrade slower or faster.
As discussed in Chapter 5, during short term (21 days) assessment showed significant in
vivo degradation of P(CL/D,LL)-PU, one of the three tested SPEUs, was observed. To
characterize degradation, we further also suggest to perform (long-term) in vivo study,
which would help further characterization of the PAU1000 and PBCL-PU in particular. The
degradation of PAU100 and PBCL-PU was assessed in vitro and can only serve as an
indication for their degradation in vivo, where enzymatically assisted degradation can
take place. Esterases (e.g. cholesterol esterase) were shown to degrade PUs in vitro27.
Hence, it is justified to hypothesize that PUs described in this thesis would undergo both
uncatalyzed and enzymatically catalyzed hydrolysis (via enzymes released by leukocytes
and giant cells). Matrix metalloproteinases (MMPs) are a family of structurally related
zinc-dependent proteolytic enzymes that are responsible for turnover of ECM proteins.
Van Amerongen et al. and Luttikhuizen et al. have successfully utilized in situ
zymography to show that MMPs assisted degradation of collagen scaffolds in vivo28, 29. As
yet, it is unknown whether MMPs could hydrolyze other bonds (i.e. urethane) than
peptide bonds. Thus, their effect on the PUs remains to be elucidated. In addition to
proteases, other degrading enzymes should also be investigated: acid phosphatase,
alkaline phosphatase, aminopeptidase, succinic dehydrogenase etc.30 In vitro
investigation of enzymes potentially involved in the biodegradation of the SPEUs will
provide tools that will help to further tailor degradation of the SPEUs in vivo.
5. Future generation “smart” SPEUs
In vitro assays showed that all the SPEUs were non-cytotoxic and highly blood
compatible (Chapters 3 and 5). In vivo, the designed SPEUs provided adequate structural
support for throughout vascularization of the scaffold and tissue formation (Chapter 5).
However, due to specificity of the different soft tissues in the body and induced
microenvironment after damage, we expect that the biologically active factors might be
required for regeneration of the specific application site. Cell/tissue interactions mainly
proceed on the biomaterial-tissue interface and should lead to specific instead of random
processes, i.e. surfaces should favor deposition of a particular set of proteins and specific
cells31, 32. In this way, instead of acting only as a simple support mash, new generation
of scaffolds would actively induce and guide specific soft tissue regeneration.
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Upgrading biodegradable scaffolds from “structural support” to guided “healing” level to
meet a particular application can be achieved via incorporation of instructive factors and
and/or cells into biodegradable scaffolds (Table 1).
Table 1. Overview of soft tissue regeneration applications.










Nerve guides Schwann cells NGF, BDNF, NT-3, GGF, FGF
Instructive factors could be introduced in the synthetic step as pendant groups to the
polymer backbone, incorporated during scaffold preparation or introduced upon
completion of the manufacturing process (e.g. via surface modification). Choice of an
appropriate method depends on compatibility between components and parameters of
the scaffold manufacturing process and stability of a biological active. In other words,
the scaffold preparation method should not impair the integrity and function of a drug,
protein or cell in question.
Processing conditions as described in this thesis (Chapter 5) would lead to either
denaturation of proteins or their loss by diffusion. This obstacle could be solved by e.g.
incorporation of protein sequences by surface modification, or by pre-encapsulation of
instructive factors in microspheres and subsequent loading of the porous scaffolds
manufactured from the SPEUs.
As presented in Chapter 3, physical deposition of protein to enhance cell adhesion
resulted in an instable layer. In turn, covalent bonding via chemical surface modification
could result in impaired protein mobility and disruption of conformation that is required
for cell binding. It has been postulated that covalent attachment of adhesive protein
sequences (short peptides) instead of whole proteins would be more beneficial in
enhancing cell adhesion33. Short peptides (e.g. RGD sequence instead of fibronectin) are
more stable against conformational change, their density on the surface can be easily
controlled and their orientation is expected to be more beneficial for ligand-acceptor
coupling and eventually cell adhesion31, 33. Surface modification of the SPEUs presented
in this thesis would comprise of an initial surface (e.g. plasma) treatment to introduce
functional groups on biomaterial surface34, 35 (hydroxyl, carboxyl and amino) followed by
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grafting of polymers with available –COOH groups and subsequent reaction with N-
terminus of peptides33.
Degradable microspheres can also be utilized to deliver instructive factors to meet a
specific application. Being chemically compatible with the SPEUs presented in this thesis,
SynBiosys™ multiblock copolymers, materials especially designed for drug delivery
purposes36 would be excellent candidates for delivery of instructive factors.
Furthermore, biodegradable PU scaffolds described in this thesis can be seeded and
cultured with relevant (stem) cells prior to implantation. To achieve such tissue
engineered construct, a bioreactor especially designed to meet a particular soft tissue
regeneration application (e.g. pulsatile flow bioreactor for TE of vascular grafts) can be
employed. Although there are some promising examples of bioreactors37, 38, this
technique would have to be custom designed per a specific application which would
endanger its commercialization. An alternative, more convenient and more effective
approach includes injecting scaffold constructs with progenitor cell dispersion shortly
prior to implantation. For instance, endothelial progenitor cells (EPCs) and their trans-
differentiated progeny39, could be seeded (injected) as smooth muscle cell equivalents
inside the wall of the porous scaffolds prepared from the SPEUs presented in this thesis.
Combined with delivery of instructive factors, such a scaffold would provide optimal
conditions for regeneration of soft tissues.
6. Concluding remarks
Segmented polyester urethanes (SPEUs) allow for wide range of properties by a choice
of building blocks and their ratio. In this thesis, we presented novel, biocompatible SPEU
scaffolds for soft tissue regeneration with an enhanced degradation when compared to
poly(caprolactone)-based SPEUs. The degradation has been tuned by introducing co-
monomers and a diisocyanate susceptible to hydrolysis. Chemically modified SPEUs
(PBCL-PUs and PAUs) were preferentially surface eroded, which is more desirable than
exclusive bulk degradation. Porous scaffolds prepared from the SPEUs were
interconnected and provided a good matrix for infiltration of leukocytes, throughout
vascularization and tissue formation in the pores. We have shown that the short-term (3
weeks) tissue response was mainly influenced by the degree of microphase separation
and the scaffold morphology. Long-term in vivo degradation of PBCL-PUs and PAU1000
should be performed with special emphases on extracellular enzymes that are associated
with degradation of biomaterials, such as esterases and proteolytic enzymes. The SPEUs
described in this thesis could be further improved to actively support and guide soft
tissue regeneration through delivery of instructive factors and hosting (progenitor) cells
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Most of the tissue engineering based regenerative therapies in order to treat damaged or
lost soft tissues depend on the use of biodegradable scaffolds. A functional scaffold
should provide a structural support whilst remaining transient until functional restoration
is achieved. Tissue restoration and function recovery can only be achieved if biomaterial
degradation, physiological turnover and new tissue formation are balanced.
Tunable mechanical properties, ease of processing and relatively good biocompatibility
render segmented polyester urethanes (SPEUs) attractive as biodegradable biomedical
materials. SPEUs based on polycaprolactone (PCL) soft segment have been thoroughly
investigated as biodegradable scaffolds for biomedical applications (e.g. meniscus
replacement). Although proven beneficial as long term implants, these materials degrade
very slowly and are therefore not suitable in applications in which scaffold support is
needed for a shorter time. Tunability of SPEUs allowed us to increase susceptibility of
these SPEUs to hydrolysis via chemical modification of either polyester soft segment or
by introducing more reactive (and hydrolyzable) hard segment. The aim of this thesis
was to design biocompatible SPEU scaffolds for soft tissue regeneration that would
gradually degrade faster than commercially available SPEUs evoking only a mild tissue
response. Cyto- and haemocompatibility of the novel SPEUs presented in this thesis were
assessed in vitro. Furthermore, we prepared porous scaffolds via a combined salt
leaching/thermally induced phase separation method and evaluated their biocompatibility
in vivo.
Chapter 1 provides an introduction into soft tissue restoration therapies and focuses
more specifically on the soft tissue regeneration by use of biodegradable polymers. In
this chapter, we also describe scaffold processing methods and degradation mechanisms
of biomaterials. Furthermore, we give an overview of the aspects involved in the
interaction of biomaterials with the surrounding tissue - biomaterial surface properties
related to cell adhesion and haemocompatibility, and foreign body reaction to
biomaterials. Finally, structure-property relationship characteristic for segmented
biomedical polyurethanes as the best candidates for soft tissue regeneration scaffolds
are discussed.
We hypothesized that the hydrolysis of PCL-based SPEUs can significantly be improved
by the introduction of a faster hydrolyzable hard segment derived from terephthaloyl
diisocyanate (TPHDI). In Chapter 2 we described the hydrolytic degradation of TPHDI-
containing polyacylurethanes (PAUs) in vitro. PAUs were shown to degrade via both bulk
and surface erosion mechanisms. Fourier Transform Infra Red (FTIR) spectroscopy was
successfully applied to study the extent of PAUs microphase separation during in vitro
degradation. Due to a faster hydrolyzable hard segment based on TPHDI and lower
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degree of microphase separation, PAUs were found to degrade much faster in vitro than
comparable PUs based on 1,4-butanediisocyanate (BDI) with the same polyester (PCL)
soft segment. Predominant chain scission at the surface led to different surface
properties of PAUs with respect to the bulk. Surface erosion and increased chain mobility
at the surface resulted in the increase of both soft and hard segment crystallinity upon
degradation. Generation of polar groups upon hydrolysis and the increase of the HS
content at the surface probably led to the increase in hydrophilicity, which further
rendered PAUs potentially cell adhesive. PAU1000 (molar mass of the oligocaprolactone
soft segment = 1000 g/mol) can be recommended as a potential scaffold material to be
used in regenerative medicine due to its optimal degradation behavior in vitro. In
Chapter 3 the potential to use PAUs as scaffolds for tissue engineering is further
investigated by assessing cell adhesion and haemocompatibility of these materials.
PAU1000 exhibited excellent haemocompatibility in vitro. In addition, PAU1000 supported
both adhesion and proliferation of vascular endothelial cells. The contact angle of
PAU1000 decreased in biological fluids. In endothelial cell culture medium the contact
angle reached 60°, which is optimal for cell adhesion. Taken together, these results
support the application of PAU1000 in the field of soft tissue repair as a temporary
degradable scaffold.
In order to design biomedical SPEUs that would hydrolyze faster than PCL-based SPEUs,
we chemically modified the soft segment too. In Chapter 4 we describe the synthesis of
γ-butyrolactone (γ-BL) and ε-caprolactone (ε-CL) co-polyesters (PBCL-PUs) by 1,4-
butanediol initiated ring-opening polymerization (ROP), catalyzed by Candida Antarctica
Lipase B (CAL-B; Novozyme 435). γ-Butyrolactone does not polymerize readily via 
conventional synthetic pathways. Enzymatic catalysis allowed for the incorporation of up
to 26 mol% of γ-BL in the oligodiols with relatively good product yield. Introduction of
hydrophilic γ-BL disturbed PCL crystallinity and resulted in enhanced hydrolytic
degradability of PBCL-PUs. Modification of the PCL-soft segment with introduction of γ-BL
resulted in twice as high hydrolysis rate of the SPEUs when compared to the SPEUs with
unmodified soft segment. The proposed manufacturing route to obtain oligodiols for the
synthesis of biomedical PUs is attractive due to the employment of the low-cost
monomers (γ-BL and ε -CL), efficiently and easily removable catalyst and low reaction
temperatures.
Soft segment modified BDI-based SPEUs were further processed into porous scaffolds
and implanted subcutaneously in rats for 21 days (Chapter 5). Tissue remodeling and
scaffold turnover was associated with a mild tissue response. This foreign body response
was characterized by extensive vascularization throughout the interconnected pores,
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with low numbers of macrophages and giant cells on the edges and extracellular matrix
components formation inside the pores of the implants. The tissue ingrowth appeared to
be related to the extent of microphase separation of the SPEUs and foam morphology. At
day 21, all of the implants were highly vascularized also confirming the superior quality
of the interconnected pore structure. At this time point, biodegradation of P(CL/D,LL)-PU
was already observed while the other two polyurethanes remained unaffected in this
relatively short period. The degradation of P(CL/D,LL)-PU proceeded without affecting
the newly formed tissue This polyurethane could be employed as a short-term
biodegradable scaffold in soft tissue (e.g. blood vessel) remodeling.
Finally, in Chapter 6 the morphological and surface properties of the novel SPEUs are
discussed with respect to their biological performance. We demonstrate that the in vitro
hydrolysis of the novel SPEUs is enhanced by the choice of soft and hard segment
building blocks. To fully characterize the in vivo degradation which is suspected to be
enzymatically catalyzed (by e.g. esterases, MMPs and other proteolytic enzymes), we
further suggest performing long-term (i.e. at least up to a year) in vivo study relevant to
a potential biomedical application. In Chapter 6 we also discuss how the SPEUs
described in this thesis could be further improved to actively support and guide soft
tissue regeneration through delivery of instructive factors and hosting progenitor cells
relevant to a particular application site. In this way, instead of acting only as a mare
support mash, new generation of “smart” SPEU scaffolds would actively induce and







De meeste op tissue engineering gebaseerde regeneratieve therapieën voor de
behandeling van beschadigd of verloren weefsel zijn afhankelijk van het gebruik van
biologisch afbreekbare scaffolds. Een functionele scaffold moet tijdelijk ondersteuning
bieden totdat functioneel herstel behaald is.
Het herstellen van functioneel weefsel is slechts mogelijk wanneer de afbraak van het
biomateriaal, de fysiologische turnover en de generatie van nieuw weefsel in balans zijn.
Gesegmenteerde polyester urethanen (SPEU's) zijn aantrekkelijke biologisch afbreekbare
scaffolds vanwege hun controleerbare mechanische eigenschappen, goede
hanteerbaarheid en goede biocompatibiliteit. SPEU's gebaseerd op polycaprolacton (PCL)
zachte segmenten zijn vaak onderzocht voor gebruik als biologisch afbreekbare scaffold
in biomedische toepassingen, bijvoorbeeld als vervanging voor de meniscus. Deze
materialen zijn erg geschikt voor gebruik in implantaten die lang blijven zitten, maar
omdat ze erg langzaam degraderen zijn ze niet geschikt voor toepassingen waar
ondersteuning slechts een korte periode nodig is. De controleerbaarheid van SPEU's
heeft ons in staat gesteld om de vatbaarheid voor hydrolyse van deze SPEU's te
verhogen via chemische modificatie van ofwel polyester zacht segment ofwel door de
introductie van reactiever (en hydrolyseerbaar) hard segment. Het doel van dit
proefschrift was het ontwikkelen van biocompatibele SPEU scaffolds die sneller
degraderen dan commerciëel verkrijgbare SPEU's voor de regeneratie van zacht weefsel.
De cyto- en hemocompatibiliteit van de in dit proefschrift beschreven SPEU's werden in
vitro bepaald. Verder werden poreuze scaffolds gemaakt via een combinatie van zout
uitlogen en thermisch geinduceerde fasescheiding, en de in vivo biocompatabiliteit van
deze scaffolds werd geëvalueerd.
Hoofdstuk 1 is een introductie in de therapieën gericht op het herstel van zacht weefsel
en is specifiek gericht op het herstel van zacht weefsel met behulp van biologisch
afbreekbare polymeren. In dit hoofdstuk worden ook methoden om scaffolds te
verwerken en de degradatiemechanismen van biomaterialen beschreven. Daarnaast
geven we een overzicht van de aspecten die een rol spelen bij de interactie van
biomaterialen met het omliggende weefsel – eigenschappen van het oppervlak van
biomaterialen in relatie tot celadhesie en hemocompatibiliteit, en de
vreemdlichaamsreactie op biomaterialen. Tenslotte worden de structuureigenschappen
die karakteristiek zijn voor gesegmenteerde biomedische polyurethanen besproken.
Wij hypothetiseren dat de hydrolyse van op PCL-gebaseerde SPEU’s significant verbeterd
kan worden door introductie van een hydrolyseerbaar hard segment afkomstig van
terephthaloyl diisocyanate (TPHDI). In hoofdstuk 2 wordt de hydrolytische degradatie
van TPHDI-bevattende polyacylurethanes (PAUs) in vitro beschreven. Wij hebben laten
zien dat PAU’s degraderen via zowel bulk als oppervlakte erosie mechanismen. Fourier
Transform Infra Red (FTIR) spectroscopie werd succesvol toegepast om te bestuderen in
welk mate PAU’s microphase scheiding ondergaan tijdens in vitro degradatie. Vanwege
een sneller hydrolyseerbaar hard segment gebaseerd op TPHDI en een mindere mate
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van microphase scheiding, degraderen PAU’s veel sneller in vitro dan vergelijkbare PU’s
gebaseerd 1,4-butaandiisocyanaat (BDI) met hetzelfde polyester (PCL) zachte segment.
Vooral ketenbreuk aan het oppervlak leidde tot andere oppervlakte eigenschappen van
PAU’s ten opzichte van de bulk. Oppervlakte erosie en een verhoogde chain mobility aan
het oppervlak leidden tot een verhoogde kristalliniteit van zowel de zachte als de harde
segmenten tijdens de degradatie. De vorming van polaire groepen tijdens degradatie en
de verhoging van de hoeveelheid HS aan het oppervlak leidden waarschijnlijk tot een
verhoging van de hydrophiliciteit, wat de PAU’s in potentie celadhererend maakte.
PAU1000 (met een molaire massa van het oligocaprolacton zachte segment van 1000
g/mol) kan aangeraden worden als een potentieel materiaal voor scaffolds voor gebruik
in regeneratieve geneeskunde vanwege zijn optimale degradatiegedrag in vitro. In
hoofdstuk 3 wordt het potentieel van PAU’s als scaffolds voor tissue engineering verder
onderzocht middels het bepalen van celadhesie en de hemocompatibiliteit van deze
materialen. PAU1000 liet een uitstekende hemocompatibiliteit zien in vitro. Verder
ondersteunde PAU1000 zowel de adhesie als de proliferatie van vasculaire endotheel
cellen. De contacthoek van PAU1000 verminderde in biologische vloeistoffen. In een
kweekmedium voor endotheelcellen werd de contacthoek 60°, wat optimaal is voor
celadhesie. Samen geven deze bevindingen aan dat PAU1000 toegepast kan worden als
tijdelijke afbreekbare scaffold binnen het veld van tissue engineering.
Om biomedische SPEU’s te ontwikkelen die sneller hydrolyseren dan op PCL-gebaseerde
SPEU’s hebben we ook het zachte segment chemisch veranderd. In hoofdstuk 4 wordt
de synthese van γ-butyrolacton (γ-BL) en ε-caprolacton (ε -CL) co-polyesters (PBCL-PUs)
via 1,4-butaandiol geïnitieerde ring-opening polymerisatie (ROP), gecatalyseerd door
Candida Antarctica Lipase B (CAL-B; Novozyme 435), beschreven. γ-Butyrolacton
polymeriseert niet gemakkelijk via conventionele synthese routes. Enzymatische catalyse
maakte de incorporatie van tot 26 mol% γ-BL in de oligodiols mogelijk, met een relatief
goede opbrengst. De introductie van het hydrophiele γ-BL verstoorde de kristalliniteit
van PCL en resulteerde in een verhoogde hydrolytische degradeerbaarheid van de PBCL-
PUs. Modificatie van het PCL-zachte segment door de introductie van γ-BL resulteerde in
een tweemaal snellere hydrolyse van de SPEU’s in vergelijking met SPEU’s met een
ongemodificeerd zacht segment. De voorgestelde synthetische route om oligodiols te
verkrijgen voor het maken van de biomedische PU’s is aantrekkelijk vanwege het gebruik
van goedkope monomeren (γ-BL and ε -CL), een efficient en makkelijk verwijderbare
catalysator en lage reactietemperaturen.
Op BDI gebaseerde SPEU’s met gemodificeerde zachte segmenten werden verder
verwerkt tot poreuze scaffolds en gedurende 21 dagen subcutaan geimplanteerd in
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ratten (Hoofdstuk 5). Het hermodelleren van weefsel en de afbraak van de scaffold
gingen gepaard met een milde weefselrespons. Deze vreemdlichaamsreactie werd
gekenmerkt door verregaande vascularisatie door de poriën van de scaffold heen, met
een paar macrophagen en giant cells aan de randen van de scaffold en de formatie van
extracellulaire matrix in de poriën van de matrix. De ingroei van weefsel leek gerelateerd
te zijn aan de mate van micophase separatie van de SPEU’s en de morphologie van het
schuim. Op dag 21 waren veel bloedvaten aanwezig in de implantaten, wat de
superieure kwaliteit van de poriënstructuur bevestigd. Op dit tijdspunt had er al
biodegradatie van P(CL/D,LL)-PU plaatsgevonden, terwijl de twee andere polyurethanen
onaangedaan bleven in deze relatief korte tijdsperiode. De degradatie van P(CL/D,LL)-PU
verliep zonder het nieuw gevormde weefsel te beïnvloeden. Dit polyurethaan zou
gebruikt kunnen worden als een snel afbreekbare scaffold voor tissue engineering van
zacht weefsel (bijv. bloedvaten).
Tenslotte worden in hoofdstuk 6 de morphologische en oppervlakte eigenschappen van
de nieuwe SPEU’s besproken met betrekking tot hun biologische prestatie. Wij laten zien
dat de in vitro hydrolyse van de nieuwe SPEU’s verbeterd is door de keuze voor zachte
en harde bouwstenen. Om de in vivo degradatie, die waarschijnlijk enzymatisch
gekataliseerd wordt (door bijv. esterases, MMP’s en andere proteolytische enzymen),
volledig te karakteriseren, stellen wij voor om een in vivo studie te doen die relevant is
voor een potentiële biomedische toepassing, over een langere periode (i.e. tenminste
een jaar). In hoofdstuk 6 bespreken we ook hoe de SPEU’s die beschreven worden in
dit proefschrift verder verbeterd zouden kunnen worden om actief tissue engineering te
ondersteunen en begeleiden middels de afgifte van instruerende factoren en incorporatie
van voorlopercellen die relevant zijn voor een specifiek toepassinggebied. Op deze
manier zou het een nieuwe generatie van “slimme” SPEU scaffolds actief tissue
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